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ABSTRACT 
 
 
Burkholderia pseudomallei (Bp) is a saprophytic, gram-negative aerobe and the 
causative agent of the disease melioidosis. Melioidosis is an infectious disease that occurs 
in humans and animals and is prevalent in Southeast Asia, northern Australia and other 
tropical areas. Transmission occurs through direct contact with the organism via 
ingestion, inhalation, or through open wounds and skin abrasions. Clinical presentation is 
extremely variable and can range from acute septicemia with bacterial dissemination to 
distant sites, to an isolated pulmonary infection. Treatment of melioidosis can be 
problematic because it is often difficult to diagnose and Bp is resistant to a diverse group 
of antibiotics. Even with treatment, the mortality rate of melioidosis is 20 to 50%. 
 
While this pathogen is not widespread in the United States, it is a significant U.S. 
health issue because of its high potential for use as a biological weapon. The US Centers 
for Disease Control and Prevention (CDC) and The Department of Health and Human 
Services (DHHS) has recognized Bp as a Tier 1 Select Agent, meaning there is no 
effective vaccine against this high morbidity/mortality disease. Furthermore, according 
the CDC, other factors including aerosol infectivity, the severity of infection, and the 
global distribution of this pathogen makes it a potential bioterrorism agent that poses a 
threat to national security, if intentionally released into populated areas. 
There has been little investigation into the role of host genetic background as it 
relates to susceptibility and/or resistance to Bp infection. It has been known for some 
time that inbred and recombinant inbred mice exhibit differences in susceptibility to 
many intracellular pathogens and are thought to provide excellent models for acute and 
chronic human melioidosis. Therefore, this project set out to identify host genetic 
elements that contribute to differential immune responsiveness and/or susceptibility to a 
Bp infection using a murine pneumonic challenge model. There is a high potential for 
discovery of host genes/genetic networks that confer resistance or sensitivity to this 
dangerous and emerging pathogen using inbred and BXD mouse strains as an in vivo 
modeling system of melioidosis. 
We have utilized recombinant inbred BXD mice and a powerful array of 
complementary computer-based modeling algorithms and databases collectively known 
as GeneNetwork. We infected parental mice and 32 BXD strains with 50-100 CFU of Bp 
(strain 1026b) and monitored survival and weight retention each day over an eleven-day 
time course. Initial studies revealed that Bp infection elicits phenotypically distinct innate 
immune responses in terms of survival and weight loss following pneumonic infection in 
parental and BXD mice. Using the computational tools in GeneNetwork, we performed 
genome-wide linkage analysis of our survival and weight loss phenotypic data to identify 
that survival is a complex trait involving loci on chromosomes 5 and 7 and weight 
retention involves loci on chromosome 12. We then analyzed and ranked several 
potential candidate genes within the significant and/or suggestive interval on these 
chromosomes that appear to correlate with differential susceptibility to Bp infection. 
Several genes have intriguing connections with innate immunity, regulation of Nf-kβ, 
  vi 
apoptosis, cell cycle regulation, nervous system development, calcium homeostasis, lipid 
transport, host cell growth and development, and autophagy. 
To date, there have been few published studies that have identified specific host 
genetic elements that correlate with resistance and/or susceptibility to the acute form of 
melioidosis. Therefore, the identification of key host genetic factors that control 
resistance or susceptibility to Bp is of much importance. Results generated from this work 
will increase our understanding of the interactions between Bp and its genetically diverse 
hosts, which will enhance the understanding of Bp pathogenesis and increase the 
biological knowledge to help guide the progression and development of preventative and 
therapeutic measures to a Bp infection as well as other high morbidity/mortality 
respiratory pathogens. 
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CHAPTER 1.     INTRODUCTION 
 
 
BURKHOLDERIA TAXONOMY AND GENOMICS 
 
Burkholderia pseudomallei (Bp) belongs to the Burkholderia genus, which 
contains over 40 species that inhabit a variety of ecological niches [1]. The majority of 
species within this genus are non-pathogenic soil-dwelling bacteria, but a few species 
(including Bp) are highly pathogenic to humans and animals, and can result in severe 
disease [2]. This includes B. mallei, an obligate mammalian pathogen and the causative 
agent of glanders. B. mallei primarily affects horses, donkeys and mules, and is extremely 
virulent in humans [1]. A clinically important species of Burkholderia is B. cenocepacia, 
which is a major cause of opportunistic infections in cystic fibrosis patients [1, 3]. This 
genus also includes the Bp-like strain B. thailandensis, which coexists in the soil in 
endemic areas, but as described in the literature, it is significantly less pathogenic than Bp 
in hamsters and mice [3, 4].   
 
Bp is an organism with a genome of great plasticity. It is also phenotypically 
versatile, and this is reflective of a highly dynamic genome influenced by processes such 
as recombination, mutations and gene acquisition through horizontal transfer [5, 6]. The 
Bp genome (reference strain K96243) is one of the most complex bacterial genomes 
sequenced to date, and possess two chromosomes of 4.07 and 3.17 megabase pairs [3, 7].  
Bp shares a common set of 2590 genes (86% of genome) with other members of the 
Burkholderia genus [3] that encode core functions such as cell growth and metabolism. 
The other 14%, known as the accessory genome, is variably present across isolates and 
encodes accessory functions such as adaptation and survival in different environments [3, 
8]. The accessory genome also contains multiple genomic islands (GI) that have been 
acquired through horizontal transfer, and act as a major source of genomic diversity [9]. 
These GI are likely associated with virulence, antibiotic resistance and the potential for 
infection. However, more studies are needed to fully understand their association with 
clinical outcomes [9, 10].   
 
 
MELIOIDOSIS 
 
 
Burkholderia pseudomallei and Melioidosis 
 
Bp is a saprophytic, gram-negative aerobe and the causative agent of the disease 
melioidosis [11]. Melioidosis is an infectious disease that occurs in humans and animals. 
It is endemic in tropical areas between latitudes 20°N and 20°S of the equator, but is most 
often reported in areas of Southeast Asia and Northern Australia [12]. In fact, this disease 
has emerged as a major public health concern in Northern Australia and Southeast Asia 
where it is the most common cause of fatal bacteremic pneumonias [13, 14] and carries a 
mortality rate of 20% and 50%, respectively [7].   
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Bp is an environmental pathogen and can be found in niches that predominate in 
the tropics, such as rice paddies, stagnant waters and moist soils, [15, 16]. It is thought 
that these habitats are the major reservoirs from which susceptible hosts acquire 
infections [16]. Infection can result from percutaneous inoculation, inhalation, or 
ingestion [3] and manifestations of disease are dependent on host pathogen interactions 
and are extremely broad. Manifestations can range from rapidly lethal sepsis to chronic 
low-grade infection, with the most common clinical picture being sepsis with bacterial 
dissemination to distant sites [11, 17-19]. This picture is frequently associated with 
pneumonia and formation of abscesses on the liver and spleen [20]. Infection can also 
manifest in the skin, in bone, joints, soft tissue, or the prostate [19, 21-23], and can also 
cause blood disease, kidney disease, heart disease, and more [20]. This broad spectrum of 
clinical symptoms has earned Bp the nickname “The Great Mimicker”, since the clinical 
symptoms of melioidosis imitate those of many other diseases. As a result, Bp infections 
are frequently misdiagnosed [24] and this is often fatal [3]. Diagnosis is then reliant on 
proper specimen collection and laboratory identification of the organism [23]. 
Additionally, melioidosis has been dubbed the “Vietnamese time bomb” [25] because of 
lengthy disease latency observed in troops of all nationalities who served in areas with 
endemic disease [25, 26]. This phenomenon has also been seen in returned travelers to 
other countries [25, 27, 28].  
 
 
Antibiotic Resistance and Treatment 
 
Melioidosis has an extremely extended progression and cure is difficult without a 
long course of antibiotic treatment [3]. To make matters worse, Bp is inherently 
resistance to many antibiotics—including penicillin [29, 30], third-generation 
cephalosporins [29, 31], aminoglycosides [29, 32, 33], rifamycins [28], tetracycline [34-
36], quinolones [30, 31, 34] and macrolides [29, 33, 35], which greatly hinders clinical 
therapeutic options. According to a recent review by Wiersinga et. al. , “various 
mechanisms of acquired antibiotic resistance have been identified in Bp and include 
efflux pumps [33], enzymatic inactivation, bacterial-cell-membrane impermeability, 
alterations in the antibiotic target site, and amino acid changes in penA (the gene 
encoding the highly conserved class A β-lactamase)” [3, 37, 38].  
 
Treatment of melioidosis lasts for 20 weeks and is divided into intravenous and 
oral phases [3]. The initial intensive phase includes 10 to 14 days of intravenous 
administration of ceftazidime, meropenem, or imipenem [3, 7, 8]. This is followed up 
with an oral eradication therapy, usually with trimethoprim-sulfamethoxazole or 
doxycycline for 3 to 6 months [3]. Despite this prolonged administration of antibiotics, 
the rate of relapse is about 10%, which increases to almost 30% if antibiotic therapy is 
discontinued at 8 weeks or less [39, 40]. The risk of relapse is also correlated to the initial 
extent of disease [28]. As compared to children, who generally have a better prognosis, 
adult patients fare worse and often require life-long follow-up [21, 41]. Unfortunately, 
melioidosis has high mortality rates (up to 50%) despite the use of aggressive 
antimicrobial therapy [1].   
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Factors Associated with Disease Acquisition 
 
Disease acquisition in endemic regions is associated with environmental and host 
factors [7]. People with occupational or recreational exposure to contaminated soil or 
water (rice farmers, military personnel, adventure travelers, eco-tourists, and construction 
workers [42]) have a higher incidence of disease. This is most common during the rainy 
season when aerosols are created, which results in repeated inhalation of Bp [43, 44]. 
Environmental sampling studies reveal there is a positive association between the 
prevalence of disease and the degree of environmental contamination [7]. In addition to 
environmental factors, data suggests that host factors play an important role in mounting 
an immune response against infectious diseases [45] such as melioidosis. While healthy 
persons can contract melioidosis, most patients in endemic regions have an underlying 
predisposition [28], which suggests that the immunological status of the patient can 
influence disease initiation and progression [15]. Specifically, diabetes mellitus (50% of 
cases) and chronic renal disease (in 10 to 27% of cases) are the most common risk factors 
for melioidosis [7, 15]. Other risk factors include heavy alcohol use, chronic pulmonary 
disease, and cancer [3, 21]. Furthermore, since melioidosis is associated with a broad 
range of clinical presentations, there is a possibility that the route of infection is one of 
the many factors that may influence disease outcome [46].  
 
It has been established through published genome wide studies that susceptibility 
to major infectious diseases in humans may be associated with common polymorphisms 
[47, 48]. These findings include a correlation between human leukocyte antigen (HLA) 
polymorphisms and the type and/or intensity of the immune response that develops in 
response to a Bp infection [49]. Additionally, a study by Nuntayunuwat et.al found that 
polymorphisms in cytokine-related genes maybe be a factor in susceptibility to infection 
with Bp [50]. Such data highlight the importance of investigating the role of host genetic 
variation with regards to susceptibility to disease [48]. This also leads to the notion that 
there may be an immunogenetic basis in clearing a Bp infection. However, the impact of 
specific genes or genetic backgrounds in humans that contribute to the susceptibility or 
resistance to many major diseases [51], including melioidosis, has yet to be determined. 
 
 
Animal Models 
 
A variety of animals have been used in experimental models of melioidosis, 
including chicken [52], rats [53], guinea pigs [54] and inbred mouse strains [55, 56]. The 
murine infection model has also been used to show both the importance of the host 
genetic background as well as host responses on the progression of a Bp infection [28].  
BALB/c mice [57, 58] and DBA/2J (D2) [55, 59] mice are known to be extremely 
susceptible to the acute form of melioidosis, while C57BL/6 (B6) [28, 55, 56, 58] mice 
exhibit a heightened level of resistance to the acute form of melioidosis, and tend to 
develop a chronic form of the disease. The acute melioidosis observed in BALB/c and D2 
mice is characterized by significantly higher levels of pro-inflammatory cytokines, 
including a hyper-production of IFN-γ. This results in a cellular response that fails to 
control the infection and contributes to tissue damage and multiple organ failure [56]. In 
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contrast, B6 mice develop a chronic infection that is associated with a moderate but 
transient induction of pro-inflammatory cytokines, allowing the temporary sequestration 
of Bp within phagocytes and induction of an adaptive immune response [56, 60]. The 
heighted level of resistance exhibited in B6 mice is thought to have a genetic basis. 
Undeniably, these mouse studies illustrate the potential importance of host genetic effects 
to Bp infection by highlighting major differences between distinctive inbred strains [48, 
56, 61].  
 
 
POTENTIAL FOR BIOTERRORISM 
 
As a result of Bp’s biodefense implications, broad-host-range infectivity and its 
low infectious dose, the CDC and DHHS have recognized Bp as a Tier 1/ Category B 
Select Agent [37, 62, 63]. According to the CDC, agents within this category are those 
that are moderately easy to disseminate, have an amenability to aerosolize, result in a 
severe course of infection and no have effective vaccine. Other factors include the 
intrinsic antibiotic resistance and global distribution of this pathogen, which makes it a 
potential bioterrorism agent that poses a threat to national security if intentionally 
released into populated areas [64, 65]. While Bp is not widespread in the U.S., it is a 
significant U.S. health issue because of its high potential for use as a biological weapon. 
In recent years, knowledge on melioidosis has increased tremendously, due to more 
research groups working with Bp as a result of it being recognized as a biological threat 
agent [66]. Furthermore, the select agent listing of this pathogen subjects all research 
using Bp to strict federal guidelines that govern its acquisition, possession and use. Only 
trained personnel within a Biosafety Level 3 (BSL-3) facility (or national equivalent) 
should handle the organism [19, 23]. This hinders research on Bp by those research 
institutions that lack these containment laboratories.   
 
 
SYSTEM GENETICS APPROACH TO MELIOIDOSIS 
 
As described above, melioidosis is associated with a variable clinical presentation. 
The varying responses have been attributed to heritable variation, which predisposes an 
individual to certain disease outcomes [67, 68]. Rather than independently investigate 
each biochemical, cellular and genetic factor in understanding melioidosis, it is far more 
efficient to instead utilize recent computational and technological advances to 
quantitatively examine large numbers of DNA sequence variations, transcript levels, and 
proteins [69, 70]. By integrating this comprehensive data, it is possible to identify the 
commonalties that link the associations between disease and DNA, as well as develop 
molecular networks by which these links can be traced [70]. As such, it is useful to 
employ a system genetics approach to identify and characterize genetic loci that 
contribute to resistance and/or susceptibility to melioidosis. 
 
System genetics is an emerging branch of systems biology that seeks to identify 
relationships between genetic variants and systems of biological components (i.e. 
molecules, cells) in complex traits and disease [71]. Most often, mapping populations are 
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used to understand the relationship between phenotype and genotype relative to complex 
traits. The phenotypic and genotypic data that is generated is compiled into complex 
networks, which are then used to discriminate genetic variation among the mapping 
population [55, 72, 73]. This approach provides an informative view into the general 
framework of complex traits and the flow of biological information [69]. Furthermore, in 
an attempt to better understand both biology and disease, systems genetics has become a 
progressively important approach in bridging this gap [69]. The idea is that variations in 
DNA (i.e. single nucleotide polymorphisms), which associate with a particular disease or 
response (melioidosis in this case), impact the complex physiological processes involved 
with the response through molecular and cellular events, tissue, and organismal 
phenotypes [70]. Statistical methods and computational algorithms can be used to 
identify associations between multi-level phenotypes and the underlying genetic variants 
as previously described [74].  
 
 
GENETIC REFERENCE POPULATIONS AND QTL MAPPING 
 
 
General Information 
Genetic reference populations (GRP) are often used in system genetics studies. 
They are well characterized genetically, and thus are ideal to examine phenotypic traits 
[69]. Usually, these populations are sets of inbred strains that have been designed to 
incorporate levels of genetic complexity that mimic aspects of human populations [75]. 
Furthermore, they are genetically stable and therefore reproducible, thereby enabling 
extensive replication studies [75, 76]. As a result, phenotypic data can be obtained over 
time from various experiments and investigators, and then integrated together [77]. 
Moreover, one of the initial motivations of using GRP is that researchers do not have to 
undergo the difficult and costly task of genotyping individuals for each experiment.  
 Recombinant inbred (RI) mouse strain lines (RILs) are a type of GRP that 
provide genetic variation for molecular genetic studies and can serve as powerful tools 
for genetic mapping. Donald Bailey and Ben Taylor first developed and characterized a 
collection at the Jackson Laboratory in the 1970s [78]. RILs can serve as powerful tools 
for genetic mapping and are commonly used in linkage studies [79] to map the locations 
of DNA sequence differences (i.e. quantitative trait loci-discussed later) that contribute to 
alterations in phenotype in these model organisms. These RILs allow tight experimental 
control [75] where variance associated with environmental factors and technical errors 
can be suppressed to low levels; and each recombinant genome is represented by an 
entire isogenic line [76]. Conventional RILs are created by crossing two inbred parental 
strains. This crossing initiates the formation of the heterozygous F1 progeny [80], which 
will be identical to its siblings. The F1 progeny are crossed to produce the F2 
generations, which is followed by repeated selfing or sibling mating for 20 or more 
generations. This breeding scheme makes certain these strains are at least 99% inbred 
[81, 82]. This also ensures fixation of the recombined chromosomes in that, animals from 
each individual RI strain are genetically identical and homozygous at every locus in their 
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genome [80, 83-85]. In other words, this process creates new RILs that: (1) possess two 
matching copies of every chromosome, (2) are genetically different from one another and 
(3) have a genome that is a pure mixture of the parental strains [79]. Additionally, RI 
strains acquire large amounts of recombination as they are created, which is particularly 
useful for mapping complex traits [79, 84, 86]. Furthermore, phenotypic data from these 
RILs can be collected by many different research groups, at different ages, and under 
various environmental conditions [87] and stored in databases for comparison [77, 88].  
 
 
The BXD Mouse Family 
BXDs (C57BL/6J X DBA/2J) are the largest RI strain panel currently available 
and represent a commonly used GRP. These strains were derived by crossing B6 and D2 
and inbreeding progeny for 20 or more generations [89] resulting in a unique 
combination of parental alleles between the different progeny strains (Figure 1-1). The 
BXD RI mapping panel was first generated by Ben Taylor at the Jackson Laboratory 
[77], producing the first 30 lines and subsequently lines 33-42 [90].  Lines 43-100+, also 
called the Advanced Intercrossed Lines (AILs), were produced by Williams, Lu and 
colleagues at The University of Tennessee Health Science Center [84]. Breeding of the 
AILs is initiated in the same manner as the RI strain sets however, mice of the F2 
generation and each subsequent generation are intercrossed for 9-14 generations before 
initiating inbreeding. As a result, the highly recombinant AIL population incorporates 
approximately 1.7 times more recombination events [91] as standard RI strains, and a 4-
8X higher level of recombination relative to the F2 intercross progeny. This level of 
recombination significantly adds to the power of the BXD RI lines as a whole in 
achieving a higher mapping precision [79, 92].   
The BXD strain set is fully genotyped and each line is genetically distinct with a 
defined and fixed genetic architecture [73]. There are currently over 100 BXD strains for 
which genotype data is publically available. They have the potential to display a broad 
range of susceptibilities to a Bp infection [89] and also provide high precision mapping 
[93]. The idea of the use of BXD mouse strains is advantageous because BXD mice 
incorporate a well-defined level of genetic and phenotypic variation. Furthermore, since 
each strain has a fixed genome, it is possible to resample a given phenotype multiple 
times. The BXD panel consists of almost 3,800 informative markers including, single 
nucleotide polymorphisms (SNPs), polymorphic insertions and deletions (indels) and 
microsatellites disturbed throughout the genome [91, 94]. This makes the discovery of 
genetic loci that contribute to quantitative traits relatively fast and straightforward. As 
stated earlier, data generated using the BXD family of strains is both “cumulative and 
comparable”[87], where phenotypes can be quantified using the same set of genotypes, 
representing yet another advantage of this RIL [95]. 
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Figure 1-1. Breeding scheme used to generate the panel of BXD recombinant 
inbred strains.  
 
BXD recombinant inbred mouse strains that were generated by the inbreeding of B6 x D2 
F1 offspring. 
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QTL Mapping  
 
Allelic variation exists among natural populations and inbred strains, and this is 
reflective of the segregation of quantitative trait loci (QTLs) [96]. QTLs are stretches of 
DNA that are closely linked to genes that underlie a phenotype of interest. QTL analysis 
has been proven to be an invaluable tool to help unravel heritable traits, by enabling 
researchers to map different quantitative traits back to the genomic location involved in 
the regulation of these phenotypes. 
 
 QTLs are identified by their linkage to polymorphic marker loci (SNPs, indels, 
microsatellites) [94] that are distributed throughout the genome of the reference 
population. A large number of these polymorphic loci are required to obtain adequate 
power for informative QTL mapping. QTLs can be identified through their genetic 
linkage to visible marker loci with genotypes that can be readily classified [94, 97]. As 
such, markers that are genetically linked quantitative trait will segregate more often with 
trait values, whereas unlinked markers will lack an association with the phenotype [94, 
98]. The principal goal of a QTL analysis is to identify all QTLs linked to a trait and 
discern whether phenotypic differences are mainly due to a few loci with large effects, or 
many loci with small effects [98]. However, QTL mapping usually results in identifying 
genes that have major effects on the trait [99] but in this instance, sample size is a critical 
factor [98]. Furthermore, an additional advantage to identifying QTLs are the insights 
gained into the development and physiology of complex traits on a molecular level [96]. 
QTL mapping has been used to successfully identify genomic regions underlying a 
variety of human diseases such as chlamydial infections [100], Influenza [73] and 
alcoholism [101].   
 
QTL mapping requires a few essential steps: initially, the trait must be measured 
in the parental (or progenitor) inbred strains that were used to create the GRP that will be 
used for the study before culminating studies in the RILs (i.e. BXD mice). Since the 
individuals in GRP have polymorphic genes (i.e. genes that exist in multiple forms), there 
is a high potential for distinctive strains to exhibit differences in phenotype. Once a 
differential phenotype is established in the parents and the RILs, the next step is to 
determine the heritability of the variation in the trait being measured. Heritability 
describes the genetic influence of the observed variation in the trait, as opposed to 
variation caused by environmental factors or technical errors. The third step is to prepare 
the phenotype and genotype data from the individuals for QTL mapping. Once this step is 
completed, interval mapping can be carried out which will identify any regions of the 
genome that may contribute to the phenotypic trait that is being measured. 
Simultaneously, statistical tests (i.e. permutation tests and bootstrapping) are performed 
to establish confidence intervals. Once a QTL has been identified, subsequent testing can 
be used to further resolve the precise location and mechanism of the gene effect [102].  
 
For this study, we used GeneNetwork (GN) to perform our QTL mapping 
analyses. GN is an extensive online tool that contains a powerful array of complementary 
computer-based modeling algorithms and databases and uses interval mapping to 
approximate the location of QTLs throughout the genome [103, 104]. These 
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bioinformatics tools allow for the reconstruction of genetic networks that confer 
resistance and/or susceptibility to many infectious diseases [105]. GN combines a large 
number of transcriptome and sequence data sets that are acquired from many species 
including humans, mice and some plants [106]. This allows for rapid integration and 
analysis of experimentally obtained phenotypes with genetic and gene expression data 
through QTL mapping. Specifically, once trait data is uploaded into GN, interval 
mapping can be completed to establish if there is a significant or suggestive linkage 
between the phenotypic trait of interest and the genotype. Permutation tests are used to 
calculate the significant (p=0.05) and suggestive values and are depicted as a likelihood 
ratio statistic (LRS). The LRS signifies that a particular region of a chromosome contains 
a gene(s) that is influencing the variation in the phenotypic trait. The higher the LRS, the 
more likely it is that a gene in that portion of the chromosome is associated with the trait 
being measured.  
 
 
ORGANIZATION OF THE DISSERTATION 
 
 The work presented in this dissertation demonstrates the use of a murine model of 
Bp infection and a forward genetics approach to gain a better understanding of the 
interactions between Bp and its hosts. We have identified several host loci that may 
contribute to resistance and/or susceptibility to a Bp infection. 
 
In chapter 3, we exploit a powerful mouse genetics resource that consists of a 
large family of BXD type recombinant inbred strains, to perform genome-wide linkage 
analysis of the weight loss phenotype following pneumonic infection with Bp. We 
initiated this project by infecting parental mice and 32 BXD strains with 50-100 CFU of 
Bp (strain 1026b) and monitored weight retention each day over an eleven-day time 
course. Using the computational tools in GeneNetwork, we performed linkage analysis to 
identify intervals on chromosomes 4, 2, 17, and 12 that appear to control the weight 
retention trait. We then analyzed and ranked positional candidate genes in these intervals, 
several of which have intriguing connections with innate immunity, calcium homeostasis, 
lipid transport, host cell growth and development, and autophagy. 
 
Based on the insights we gained in chapter 3, we extended our investigation 
beyond weight retention to examine survival and time-to-death following pneumonic Bp 
infection. The results in chapter 4 show that D2 mice are significantly more susceptible to 
pneumonic Bp infection than B6 mice. We then utilized the BXD RI strain panel to 
perform genome-wide linkage analysis using survival and time-to-death (following 
pneumonic infection with 50-100 CFU of Bp 1026b) as phenotypic readouts. The BXD 
mice displayed a wide range of susceptibilities to pneumonic Bp infection and these 
studies revealed that survival is a complex trait that is dependent on host loci located on 
chromosomes 5 and 7.  
 
This dissertation also explores the challenges of working with infectious agents 
(such as Bp) in BSL-3 level containment laboratories. In chapter 5, we characterize the 
effectiveness of paraformaldehyde fixation for inactivation of cell samples infected with 
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Bp and Francisella tularensis (Ft). Both of these intracellular pathogens are Tier 1 select 
agents and require BSL-3 containment. In this study, we tested varying concentrations 
(0.5%, 1.0%, 2.1%, 4.2%) of paraformaldehyde to validate the inactivation kinetics 
required to completely inactivate these bacteria to allow for removal of samples from a 
BSL-3 laboratory for flow cytometric analysis using BSL-2 containment practices. We 
found that these cells are completely inactivated via a 5-minute treatment with 4% 
paraformaldehyde and that Bp is significantly more sensitive to paraformaldehyde 
treatment than Ft [107].    
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
BACTERIAL STRAINS AND GROWTH CONDITIONS 
 
Burkholderia pseudomallei strain 1026b (Bp) was obtained from BEI Resources 
Biodefense & Emerging Infections Research Resources Repository (Manassa, VA). Bp 
was cultured in LB broth (tryptone [10g/liter], yeast extract [5g/liter], and NaCl 
[10g/liter]). Challenge stocks were prepared by performing an overnight culture that was 
then sub-cultured the following day until mid-log growth phase was achieved (ABS=1.0 
at 600nm). Bacteria were then pelleted by centrifugation, resuspended in fresh LB 
medium containing 20% glycerol, and frozen in aliquots. These challenge stock aliquots 
were stored at -80˚C until needed. All work with Bp was performed under biosafety 
level-3 (BSL-3) containment according to policies and standard operating procedures 
approved via the University of Tennessee Health Science Center (UTHSC) Committee 
On Biocontainment and Restricted Entities (COBRE), a subcommittee of the UTHSC 
Institutional Biosafety Committee (IBC). The UTHSC has been approved for select agent 
work by the CDC. 
 
 
MICE 
 
C57BL/6J, DBA/2J, and all BXD strains of mice used in these studies were 
obtained from our in-house breeding colony in the Regional Biocontainment Laboratory 
(RBL) at UTHSC and were used between the ages of 8-16 weeks. Mice were housed in 
an AALAC accredited and CDC-select agent program approved facility within an 
Allentown Biocontainment Unit BCU2000 caging system with gamma-irradiated food 
and autoclaved water available ad libitum. All experimental protocols involving animals 
were reviewed and approved by the UTHSC IACUC. 
 
 
INTRANASAL INSTILLATION OF MICE WITH BP 
 
Prior to each challenge procedure, an aliquot of frozen challenge stock was 
thawed and diluted as needed with PBS to reach the required dose of Bp (50-100 
CFU/dose). Prior to instillation, mice were anesthetized using isoflurane delivered using 
a SurgiVet® Vaporstick small animal anesthesia machine equipped with a Classic T3™ 
isoflurane vaporizer (Smith Medical, Dublin, OH). Mice were exposed to 2.5% isoflurane 
delivered in O2 (2 L/min) within a 1-liter induction chamber until a state of areflexia was 
reached. Intranasal administration of each challenge dose (50μl total volume) was 
administered immediately after the mouse was removed from the induction chamber by 
pipetting the inoculum onto the outer edge of the nares. No supplemental anesthesia or 
oxygen was administered following removal of mice from the induction chamber. Mice 
were held in a tilted supine position with their heads elevated to between 60 and 75 
degrees above their feet during and after instillation (for approximately 1 minute). 
 
  12 
BP BURDEN ENUMERATION 
 
Determination of Bp burdens in the lungs and livers collected from infected mice 
was performed via dilution plating as previously described [108-110]. Briefly, lungs of 
Bp-infected mice were removed aseptically and homogenized (using a closed tissue 
grinder system, Fisher Scientific, Pittsburgh, PA) in one ml of sterile PBS, and the final 
volume was adjusted to 1.25 ml with PBS. To disrupt cells (releasing Bp), 0.25 ml 
disruption buffer (2.5% saponin, 15% BSA, in PBS) was added with light vortexing. 
Appropriate dilutions of each sample were then plated in duplicate using an Eddy Jet 
spiral plater (Neutec Group Inc., Farmingdale, NY) on LB agar plates and incubated at 
37?C for 48-72 hours. Colonies were counted using a Flash & Go automated colony 
counter (Neutec Group Inc.). 
 
 
MONITORING OF MICE POST CHALLENGE 
 
Mice were observed daily for signs of morbidity for a period of 10-11 days post 
infection. Each mouse was weighed daily as an additional measure of disease 
progression. Moribund mice were euthanized to prevent unnecessary pain and/or 
discomfort. Scoring for linkage analyses was as follows: mice that succumbed to acute 
melioidosis where given a score of “0” while those that survived were given a score of 
“1”. 
 
 
RNA ISOLATION AND FUNCTIONAL GENOMICS 
 
RNA expression was analyzed in lungs, 24 hours post-infection from resistant 
(BXD50, BXD70) and susceptible (BXD63, BXD09, BXD27) BXD mice infected with 
50-100 CFU of Bp 1026b. A minimum of three RNA samples per strain was obtained.  
For RNA isolation, lungs were immediately suspended in 1mL of RNAlater (Qiagen, 
Valencia CA) and placed in 4°C. Following homogenization (using a closed tissue 
grinder system, Fisher Scientific, Pittsburgh, PA) total RNA was prepared from the lungs 
and submitted to a cleanup protocol using the RNeasy Midi Kit (Qiagen, Valencia CA) 
following the manufacturer’s protocol. Contaminating DNA was removed using a 
RNAase-Free DNAase Set according to the manufacturer’s protocol (Qiagen, Valencia 
CA).  
 
RNA quality was confirmed by UV spectrophotometry and RNA quantity was 
confirmed by analysis on an Agilent 2100 bioanalyzer (Agilent Technologies, Santa 
Clara, CA). Total RNA was processed in the Molecular Resource Center at UTHSC.  
RNA-seq reads were trimmed to remove low quality 3’ ends using Trimmomatic (version 
0.32) with the following parameters: TRAILING:15 SLIDINGWINDOW:5:15 
MINLEN:35.  Reads were aligned to the C57BL/6J reference mouse genome (mm10) 
using TopHat2 (a splice aware aligner, version 2.0.12) with the following parameters: --
library-type fr-firststrand  --max-intron-length 300000 --b2-sensitive. HTSeq-count 
(version 0.6.1) was used with the following parameters: --stranded=reverse -r 'pos' to 
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count the number of reads that overlap each transcript in the mouse Ensemble gene model 
(GRCm38, version 76). The resulting count files were used as input to DESeq2 (version 
1.3.69).  DESeq2 uses a negative binomial distribution for statistical inference about 
differential expression of genes. We selected genes that showed differential expression 
between x and y at FDR of 0.05.  
 
 
GENOME-WIDE LINKAGE ANALYSIS 
 
QTL/interval mapping of BXD weight retention and survival phenotypic data was 
performed using GeneNetwork (www.genenetwork.org). Interval mapping tests for the 
presence of QTLs across the entire genome and summarizes the strength of linkage as a 
likelihood ratio statistic (LRS) [84, 103]. We used a permutation test to establish 
empirical significance criteria at a genome-wide p value of .05 [100]. The original data 
sets can be obtained at www.genenetwork.org with the following identification numbers: 
survival: 16330, time of death: 16331, percentage weight loss Day 1: 16332, Day 2: 
16333, Day 3: 16334, Day 4: 16335, and Principle component 1: 16350.  
 
 
HERITABILITY CALCULATION 
 
To assess heritability, we computed a single factor ANOVA with the mouse 
strain as the independent measure and percentage weight loss as the dependent measure. 
In short, the variance between strains and variance within strains were calculated. The F-
statistic was calculated as the ratio of the variance between strains to the variance within 
strains. The total variance was calculated as the sum of variance between strains and 
variance within strains. Heritability was calculated as ratio of variance between strains to 
the total variance.  
 
 
STATISTICAL METHODOLOGY 
 
Statistical analyses for some figures in chapter 3 were performed using GraphPad 
Prism software (GraphPad Software, La Jolla, CA) as indicated in the figure legend. All 
other statistical analyses were performed using the algorithms built into GeneNetwork or 
as described in the text.   
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CHAPTER 3.    GENETIC CONTROL OF WEIGHT LOSS DURING 
PNEUMONIC BURKHOLDERIA PSEUDOMALLEI INFECTION? 
 
 
INTRODUCTION 
 
Burkholderia pseudomallei (Bp) is a saprophytic, gram-negative aerobe and the 
causative agent of the disease melioidosis [7].  Melioidosis is an infectious disease that 
occurs in humans and animals and is prevalent in S.E. Asia, N. Australia and other 
tropical areas [111].  Transmission occurs through direct contact with the organism via 
ingestion, inhalation, or through open wounds and skin abrasions [7]. Clinical 
presentation is extremely variable and can range from acute septicemia with bacterial 
dissemination to distant sites, to an isolated pulmonary infection [7, 8]. Treatment of 
melioidosis can be problematic because it is often difficult to diagnose and Bp is resistant 
to a diverse group of antibiotics [34]. Even with treatment, the mortality rate of 
melioidosis is 20 to 50% [21, 112]. Although this pathogen is not endemic in the United 
States, it is a significant U.S. health issue because of its high potential for use as a 
biological weapon [56, 113]. In fact, Bp has been classified as a Tier 1 Select Agent by 
APHIS and DHHS and as a Biodefense category B pathogen by NIAID.  Furthermore, 
other factors including aerosol infectivity, the severity of infection, and the global 
distribution of this pathogen makes it a potential bioterrorism agent that poses a threat to 
national security, if intentionally released into populated areas [114].   
 
The basis of the variable progression of melioidosis in Bp-infected individuals has 
not been determined, to date. There is evidence that differential susceptibility to Bp has 
an immunogenetic basis. For instance, one study revealed that polymorphisms in 
cytokine-related genes may be a factor in susceptibility to infection with Bp [68].  
Another report revealed a correlation between human leukocyte antigen (HLA) 
polymorphisms and the type and/or intensity of the immune response that develops in 
response to a Bp infection [49]. These findings are not surprising in light of findings that 
genetic factors play a key role in susceptibility to a wide range of other infectious 
diseases. Published findings have identified host genetic factors that are critical for 
variable susceptibility to intracellular parasites [115], viruses [116-120], and both 
intracellular [74, 100, 121] and extracellular [122] bacterial pathogens. Moreover, recent 
genome-wide studies have established novel associations between common 
polymorphisms and susceptibility to several infectious diseases that are responsible for 
significant morbidity and/or mortality in humans [73, 100, 123, 124]. 
 
The murine model of B. pseudomallei infection is considered to be an excellent 
model for both the chronic and acute forms of human melioidosis [56, 60, 125]. Studies 
                                                 
 
*Reprinted with permission.  Emery, F.D., et al., Genetic control of weight loss during 
pneumonic Burkholderia pseudomallei infection. Pathogens and disease, 2014. 71(2): p. 
249-64. 
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in inbred strains of mice have established the importance of the host genetic background 
on the progression of Bp infection. C57BL/6J (B6) mice are known to be relatively 
resistant to the acute form of melioidosis and tend to develop disease that progresses 
significantly slower than that observed in the much more susceptible BALB/c [56, 60] or 
DBA/2J (D2) [61] inbred strains. To date, there have been few published studies that 
have identified host-genetic elements that correlate with the progression of melioidosis. 
In this report, we have used a panel of recombinant inbred (RI) mouse strains, that were 
generated by inbreeding of B6 x D2 F1 offspring (BXD), to perform genome-wide 
linkage analysis for the identification of host genetic loci that correlate with the 
differential weight loss of B6 and D2 parental strains during acute pneumonic 
melioidosis. 
 
 
RESULTS 
 
Our initial studies with a pneumonic challenge model (intranasal instillation) 
using 50–200 CFU of Bp 1026b confirmed the previously published observation [61] that 
B6 are more resistant than D2 to Bp infection (Figure 3-1). Subsequent studies in a 
cohort of BXD strains (using a challenge dose of 50–100 CFU) revealed a range of 
susceptibility to melioidosis. Interestingly, female D2 mice (as well as females of several 
BXD strains) were significantly more resistant to pneumonic Bp infection than their male 
counterparts (Figure 3-2). This result indicates that there are sex-based host factor(s) that 
influence the susceptibility/resistance phenotypes of at least some mouse strains to Bp 
infection. Based on these findings, we performed all of the following studies exclusively 
in male mice.  
 
We performed a series of experiments in which a cohort of 32 BXD strains as 
well as the B6 and D2 parental strains were challenged via intranasal instillation with 50–
100 CFU of Bp 1026b and then monitored for disease progression by measuring weight 
loss over the next 11 days (see Table A-1 in Appendix for BXD strain group sizes).  
Based on survival, the BXD strains could be logically broken into three categories based 
on their susceptibility to pneumonic Bp infection: 1) susceptible, 2) intermediate 
susceptibility, and 3) resistant. An evaluation of weight loss in these three groups of BXD 
genotypes predictably revealed that the resistant strains generally lost less weight than the 
intermediate susceptibility strains, and especially the susceptible BXD strains following  
infection (Figure 3-3). However, there were several BXD genotypes that did not follow 
this pattern. For instance BXD9 was highly susceptible to Bp infection and all succumbed 
to infection by day 4 post-infection. Interestingly, these mice lost less of their body 
weight than most of the strains in the study, including the BXD genotypes that were 
resistant to Bp. Likewise, BXD81 lost weight slower than the other susceptible strains 
despite the fact that they all succumbed to melioidosis by day 4 post-infection. In 
contrast, BXD38 survived the challenge while losing weight faster than any other strain 
in the study. Moreover, BXD strains within each of these phenotypically distinct 
subgroups—susceptible, intermediate susceptibility, and resistant—displayed a wide 
range of weight change kinetics (Figure 3-4). These findings indicated that weight  
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Figure 3-1. DBA/2J mice are significantly more susceptible than C57BL/6J mice 
to Burkholderia pseudomallei.  
 
Panel A: C57BL/6J and DBA/2J mice (15/strain) were challenged with 50 CFU Bp 
1026b via intranasal instillation. Mice were sacrificed (5/strain) each day and lungs were 
collected via sterile dissection. The bacterial burdens in the lungs of each mouse were 
determined via dilution plating and are reported as CFU/mg of lung tissue. Statistical 
analysis was performed using a two-way ANOVA with Bonferroni posttests. Panel B: 
C57BL/6J and DBA/2J mice (13/strain) were challenged with 50-100 CFU Bp 1026b via 
intranasal instillation and were monitored for survival over the next 11 days. Statistical 
analyses were performed using Log-Rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon 
tests. 
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Figure 3-2. Differential susceptibility of male versus female DBA/2J and BXD 
mice to pneumonic B. pseudomallei infection.  
 
The indicated strains of mice were challenged with 50-100 CFU of Bp via intranasal 
instillation and were monitored for survival over an 11-day period. Survival data is 
displayed in a Kaplan-Meier plot and statistical analyses were performed using Log-Rank 
(Mantel-Cox) tests. 
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Figure 3-3. Weight loss of BXD genotypes following pneumonic Bp infection.  
 
The cohort of BXD mice were weighed daily following intranasal instillation with 50-100 
CFU of Bp 1026b as a measure of morbidity. For comparative purposes, the data are 
presented in three panels depending on the susceptibility of each strain to Bp infection. 
The genotypes that all experienced 100% mortality are shown in the panel labeled 
“Susceptible”. Those that experienced 100% survival are shown in the panel labeled 
“Resistant”. The genotypes that had at least one survivor or at least one mortality are 
shown in the panel labelled “Intermediate Susceptibility”. The data are plotted as the 
mean weight loss (± SEM).  
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Figure 3-4. Bar graph (by rank) of percentage weight loss on days 1 through 4 
post-Bp infection.  
 
The BXD and parental mouse cohort were weighed daily after intranasal challenge with 
50-100 CFU of Bp 1026b as a measure of morbidity and the percentage of weight loss 
(mean ± SEM) is shown for each mouse genotype on the indicated day post-infection. 
The “susceptible” strains (100% mortality) are indicated with a grey bar, “resistant” 
strains (100% survival) are indicated with a white bar, and “intermediate” strains (at least 
one mouse died) are indicated with crosshatched bars. The parental B6 and D2 mice are 
indicated with black and brown bars, respectively. Red asterisks indicate that at least one 
mouse from that genotype succumbed to infection.  
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change kinetics generally tracks with disease progression, but is not a completely reliable 
indicator of susceptibility to pneumonic Bp infection. 
 
 
Heritability and Variance of Weight Loss Traits 
 
We estimated heritability as the main effect on body weight relative to the starting 
weight by ANOVA. Heritability increased from day 1 through to day 3–4 from ~70 to 
93% (Figure 3-5a). Correlations among the four sequential and non-independent weight 
loss estimates are high, and the first principal component accounts of ~75% of the total 
variance (Figure 3-5B and Figure 3-5C), and GeneNetwork Trait 16350 for the 
eigentrait associated with the principal component.   
 
 
Identification of Host Loci that Are Covariant with Weight Loss during Pneumonic 
Bp Infection 
 
We performed genome-wide linkage analysis using weight loss relative to 
baseline. Mapping results are volatile for days 1 and 2 (Figure 3-6), with suggestive loci 
on Chr 4 (LRS of ~15 from 7 to 11 Mb with B alleles contributing to increased weight 
loss; Figure 3-7A), on distal Chr 2 (LRS of ~12 from 178 to 182 Mb, high B allele; 
Figure 3-7B), and on proximal Chr 17 (LRS of ~14 from 6 to 13 Mb, high D allele; 
Figure 3-7C).  Two of these suggestive loci have an effect that does not conform to 
expectation based on parental strain weight loss (D2 high, B6 low). In contrast, we detect 
a single significant and consistent QTL on Chr 12 for weight loss on days 3 and 4 (and 
remaining stable over the remaining timecourse: see Figure A-1) that does conform to 
expectation based on the parental strain difference (Traits 16334 and 16335). This Chr 12 
locus peaks between 80 and 87 Mb near the Ttc9 gene. The LRS peak of 16–18 is near 
the genome-wide significance threshold. Although it does not affect the position of this 
peak, the LRS is boosted to 21 by including parental phenotypes (Figure 3-7D). As 
shown in Figure 3-5, a principal component analysis for weight loss at all days, also 
supports a single locus on Chr 12 with increased sensitivity being associated with the D 
allele (Trait 16350).  
 
 
Identification of Candidate Host Genes that May Contribute to Weight Loss 
Kinetics Following Pneumonic Bp Infection 
 
We analyzed each of the loci to identify and evaluate potential candidate genes. 
We considered and weighted several factors including: (1) mRNA expression levels at or 
above background in the lungs and spleen, (2) genes that are associated with local genetic 
control (so called cis eQTLs) in the lung; and (3) genes with one or more 
nonsynonymous SNPs or indels between the parental B6 and D2 genotypes. These 
factors were combined into a ranking score scale (0 to 4) using the QTLminer software 
[126]. The highest scoring candidates are indicated in Figure 3-7 (right hand panels).  
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Figure 3-5. Principal component analysis, heritability, and correlations among 
weight loss traits during the early stages of pneumonic melioidosis.  
 
Panel A: Heritability of weight loss increases from day 1 to day 4. Panel B: A 
correlation matrix of Pearson (lower left) and Spearman rank (upper right) correlations, 
along with the first principal component (PC). The numbers listed in orange or red text 
indicate correlation indices of 0.5-0.7 and 0.7 to 1.0, respectively. Panel C: Pearson’s 
Scree plot shows that the first PC accounts for approximately 75% of the strain variance 
in weight loss.  
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Figure 3-6. Genome-wide linkage analysis for percentage weight loss over the 4 
days following pneumonic challenge with Burkholderia pseudomallei.  
 
Genome-wide interval maps of percentage weight loss of all BXD genotypes and parental 
strains at each time point are shown as indicated. The blue line indicates LRS scores 
across the entire genome. Thin red and green lines indicate that B6 or D2 alleles increase 
trait values, respectively. The mouse chromosomes are identified in the upper x-axis, the 
lower x-axis shows the physical map in mega bases for each chromosome, and the y-axis 
represents the LRS score. Thick red and grey horizontal lines indicate the genome-wide 
significance threshold (p<0.05) or suggestive threshold (p<0.63), respectively. 
  
  23 
 
 
 
Figure 3-7. Detailed maps of the QTLs contributing to weight loss during the 
early stages of pneumonic Bp infection.  
 
The critical intervals on Chrs 4 (Panel A), 2 (Panel B), 17 (Panel C) and 12 (Panel D) 
were identified based on bootstrap analysis (frequencies of peak LRS indicated with 
yellow bars) and peak shapes. The critical intervals for candidate gene analysis for each 
chromosome were:  Chr 4:  7-14 Mb, Chr 2:  179.25-180 Mb, Chr. 17:  9.5-11.5 Mb, Chr. 
12: 80-86 Mb. The density of SNPs present in the BXD strains is indicated by orange 
chatter along the x-axis. The multicolored chatter along the top of the graph represent the 
open reading frames within the interval. The blue line indicates LRS scores across the 
entire genome. Thin red and green lines indicate that B6 or D2 alleles increase trait 
values, respectively. The mouse chromosomes are identified in the upper x-axis, the 
lower x-axis shows the physical map in mega bases for each chromosome, and the y-axis 
represents the LRS score. Thick red and grey horizontal lines indicate the genome-wide 
significance threshold (p<0.05) or suggestive threshold (p<0.63), respectively. Right 
hand panels: The highest ranking candidate genes within each interval (according to 
QTLminer scores) are indicated along with their LRS score and their relative expression 
levels in normative tissues.  
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More comprehensive lists of candidates for each of the QTLs are shown by day and trait 
identifiers in Tables 3-1, 3-2, and 3-3. 
 
 
DISCUSSION 
 
Both humans and distinct inbred mouse strains display a range of disease 
progression following Burkholderia pseudomallei infection. In this study, we employed a 
panel of recombinant inbred BXD genotypes to identify regions of the murine genome 
that are responsible for their variable weight loss during the course of Bp infection. We 
performed genome-wide linkage analysis using percentage weight loss over a four-day 
time course following pneumonic infection with Bp 1026b to identify host genes 
responsible for differential progression of melioidosis. We found that the weight loss trait 
is controlled in a time-dependent manner by a significant QTL on Chr 12 and several 
suggestive loci on chromosomes 2, 4, and 17. The locus on Chr 12 is likely to be the 
single primary factor responsible for differential weight loss following infection. 
Interestingly, in a parallel study in which we have used survival as the key outcome 
phenotype, we identified a highly significant QTL on Chr 5, with no contribution from 
Chr 12.  
 
Analysis of weight loss phenotypes over the course of infection yielded some 
interesting findings. First, the cohort of BXD genotypes displayed a wide range of weight 
loss kinetics that often did not always correlate with survival. For instance, BXD9 lost 
weight more slowly than other strains, yet all of these animals succumbed to melioidosis 
on or before day 4. In contrast, several genotypes that lost much more weight (and lost it 
more rapidly) than BXD9 fell into the resistant category (100% survival). These findings 
clearly showed that weight loss is not an ideal indicator for determining the ultimate fate 
of Bp-infected mice. It seems likely that other infection models would display a similar 
lack of correlation between weight loss kinetics and eventual mortality, a point that 
should be shared with IACUC committees that require sacrifice of infected animals once 
they reach an arbitrary percentage of weight loss.  
 
Another interesting finding is the volatile nature of the set of three suggestive 
QTLs detected only during the early stages of infection. These loci may be a sampling 
artifact, but it is also possible that different phases of infection expose different gene loci.  
The locus on chromosome 4 is only detected “acutely” at 24 hours post-infection. 
Similarly, the two suggestive loci on day 2 are not even hinted at either on day 1 or day 3. 
In contrast, the QTL that we detect on days 3 and 4 is consistent, and is also detected 
when mapping with the weight loss “eigentrait” that summarizes weight loss across all 
days. These findings suggest that weight loss following Bp infection may be a dynamic 
phenotype that involves different host genes over the course of infection/disease. 
Interestingly, a recently reported genome wide study of host response to H1N1 influenza 
infection also identified multiple QTLs (different from those identified here) that appear 
to control weight loss kinetics in a time-dependent fashion [73]. 
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Table 3-1.    QTLMINER scores for candidate genes within the day 1 QTL interval 
(Chr 4): Trait 16332. 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score    
(1-4) 
Chromosome 4  
 
Car8 8.07 carbonic 
anhydrase 8 
phosphoinositide-
mediated signaling, one-
carbon metabolic 
process 
184 9 Yes  4 
 
Ints8 11.13 integrator 
complex 
subunit 8 
  35 4 Yes  4 
 
Asph 9.38 aspartate-beta-
hydroxylase 
oxidation reduction, 
face morphogenesis, 
palate development, 
peptidyl-amino acid 
modification, limb 
morphogenesis, negative 
regulation of cell 
proliferation 
pattern specification 
process, peptidyl-
aspartic acid 
hydroxylation 
47 35 Yes  4 
 
Trp53in
p1 
11.08 transformation 
related protein 
53 inducible 
nuclear protein 
1 
apoptosis, cell cycle 
arrest, response to 
stress, induction of 
apoptosis 
18 1 No 3 
 
Plekhf2 10.92 pleckstrin 
homology 
domain 
containing, 
family F (with 
FYVE 
domain) 
member 2 
phospholipid binding, 
metal ion binding 
10 1 No 3 
 
2610301
B20Rik 
10.80 RIKEN cDNA 
2610301B20 
gene 
unknown 17 3 Yes  3 
 
Rbm35a 11.26 RNA binding 
motif protein 
35A 
mRNA processing, 
RNA splicing, 
regulation of RNA 
splicing 
22 2 No 3 
 
5730591
J02Rik 
9.70 RIKEN cDNA 
5730591J02 
gene 
unknown 72 5 Yes  3 
 
Ccne2 11.12 cyclin E2 cell cycle, cell division, 
regulation of cell cycle, 
DNA replication 
initiation 
4 2 No 2 
 
Runx1t1 13.67 runt-related 
transcription 
factor 1; 
translocated 
to, 1 (cyclin 
D-related) 
transcription, regulation 
of transcription, DNA-
dependent fat cell 
differentiation, 
regulation of DNA 
binding 
8 8 No 2 
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Table 3-1.    (Continued). 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score    
(1-4) 
 
Chd7 8.62 chromodomai
n helicase 
DNA binding 
protein 7 
transcription, chromatin 
modification, regulation 
of transcription, 
chromatin assembly or 
disassembly, adult 
walking behavior, heart 
morphogenesis, female 
genitalia development, 
camera-type eye 
development 
blood vessel 
development, blood 
circulation, adult heart 
development,nose 
development, embryonic 
hindlimb 
morphogenesis, palate 
development, positive 
regulation of 
multicellular organism 
growth, in utero 
embryonic development, 
sensory perception of 
sound 
ear morphogenesis, 
inner ear morphogenesis 
locomotory behavior 
6 0 No 2 
 
 
Tox 6.61 thymocyte 
selection-
associated 
HMG box 
gene 
DNA binding, T-cell 
devolopment 
0 5 Yes  2 
 
E13001
6E03Rik 
11.49 RIKEN cDNA 
E130016E03 
gene 
DNA repair, 
transcription, regulation 
of transcription, double-
strand break repair via 
homologous 
recombination, response 
to DNA damage 
stimulus, response to 
drug, response to 
ionizing radiation 
28 3 No 2 
 
Dpy19l4 11.19 dpy-19-like 4 
(C. elegans) 
C-mannosylation of 
tryptophan residues  
18 3 unknown 2 
 
1700123
O12Rik 
10.44 RIKEN cDNA 
1700123O12 
gene 
unknown 6 14 No 2 
 
RlBp1l
1 
9.20 retinaldehyde 
binding 
protein 1-like 
1 
transport 25 7 unknown 2 
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Table 3-1.    (Continued). 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score    
(1-4) 
 
4930412
C18Rik 
9.70 RIKEN cDNA 
4930412C18 
gene 
unknown 80 5 unknown 2 
 
Rab2 8.46 RAB2, 
member RAS 
oncogene 
family 
GDP binding, GTP 
binding 
5 12 unknown 2 
 
2310030
N02Rik 
10.98 RIKEN cDNA 
2310030N02 
gene 
unknown 7 1 unknown 2 
 
1110037
F02Rik 
11.41 RIKEN cDNA 
1110037F02 
gene 
RNA splicing, mRNA 
processing 
26 9 unknown 2 
 
Rbm12b 12.07 RNA binding 
motif protein 
12B 
RNA binding, 
nucleotide binding 
5 0 No 1 
 
Gdf6 9.77 growth 
differentiation 
factor 6 
growth, BMP signaling 
pathway 
1 0 No 1 
 
LOC242
317 
10.37 similar to L-
lactate 
dehydrogenase 
A chain 
(LDH-A) 
(LDH muscle 
subunit) 
(LDH-M) 
unknown 0 1 unknown 1 
 
A63003
4I12Rik 
11.10 RIKEN cDNA 
A630034I12 
gene 
unknown 0 2 unknown 1 
 
1700123
M08Rik 
11.89 RIKEN cDNA 
1700123M08 
gene 
unknown 0 1 unknown 1 
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Table 3-2.    QTLMINER scores for candidate genes within day 2 QTL intervals 
(Chrs 2 and 17): Trait 16333. 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score    
(1-4) 
Chromosome 2              
 
Lama5 179.91 laminin, 
alpha 5 
cell adhesion, regulation 
of cell migration, 
regulation of cell 
adhesion,regulation of 
embryonic development 
hair follicle development, 
muscle organ development 
lung development, 
branching involved in 
ureteric bud 
morphogenesis, organ 
morphogenesis, cilium 
assembly 
neural crest cell 
migration,branching 
morphogenesis of a 
tube,morphogenesis of a 
polarized epithelium, 
regulation of cell 
proliferation, 
morphogenesis of 
embryonic epithelium, 
odontogenesis of dentine-
containing tooth 
branching involved in 
salivary gland 
morphogenesis 
58 5 Yes 4 
 
GtpBp5 179.81 GTP binding 
protein 5 
ribosome maturation 
process, GTPase 
8 1 Yes 4 
 
Psma7 179.77 proteasome 
(prosome, 
macropain) 
subunit, 
alpha type 7 
proteolysis involved in 
cellular protein catabolic 
process, ubiquitin-
dependent protein 
catabolic process 
2 0 Yes 3 
 
OsBpl2 179.85 oxysterol 
binding 
protein-like 
2 
transport, lipid transport, 
steroid metabolic process 
8 5 No 3 
 
Ss18l1 179.78 synovial 
sarcoma 
translocation 
gene on 
chromosome 
18-like 1 
transcription, chromatin 
modification, regulation of 
transcription, regulation of 
transcription, DNA-
dependent 
dendrite development 
18 0 Yes 3 
 
Cdh4 179.18 cadherin 4 cell adhesion, axon 
guidance, positive 
regulation of axon 
extension, heterophilic 
cell-cell adhesion, 
homophilic cell adhesion 
14 57 No 2 
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Table 3-2.    (Continued). 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score    
(1-4) 
 
Taf4a 179.65 TAF4A 
RNA 
polymerase 
II, TATA 
box binding 
protein 
(TBP)-
associated 
factor 
transcription from RNA 
polymerase II promoter, 
ovarian follicle 
development, regulation of 
transcription from RNA 
polymerase II promoter 
3 0 No 2 
 
Adrm1 179.91 adhesion 
regulating 
molecule 1 
proteasomal ubiquitin 
receptor, regulation of 
deubiquitinating enzyme 
9 0 No 2 
 
Hrh3 179.83 histamine 
receptor H 3 
G-protein coupled 
receptor protein signaling 
pathway, signal 
transduction,negative 
regulation of adenylate 
cyclase activity, elevation 
of cytosolic calcium ion 
concentration, learning 
memory, negative 
regulation of glutamate 
secretion, negative 
regulation of gamma-
aminobutyric acid 
secretion, regulation of 
norepinephrine secretion, 
negative regulation of 
serotonin secretion 
response to organic cyclic 
substance, eating behavior 
drinking behavior, 
negative regulation of 
blood pressure, positive 
regulation of epithelial cell 
proliferation, cognition 
3 0 No 1 
 
4930449
I21Rik 
179.39 RIKEN 
cDNA 
4930449I21 
gene 
unknown 0 1 No 1 
         
Chromosome 17              
 Pacrg 10.60 Park2 co-
regulated 
Functions within a 
multiprotein E3 ubiquitin 
ligase complex  
36 19 Yes 4 
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Table 3-2.    (Continued). 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score    
(1-4) 
 Qk 10.40 quaking vasculogenesis, cell 
differentiation, transport, 
regulation of translation, 
multicellular organismal 
development, RNA 
splicing, mRNA transport, 
mRNA processing, axon 
ensheathment, 
myelination, muscle cell 
differentiation, long-chain 
fatty acid biosynthetic 
process 
2 1 No 3 
 Pde10a 8.99 phosphodiest
erase 10A 
signal transduction, cAMP 
catabolic process, cGMP 
catabolic process 
8 10 No 2 
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Table 3-3.     QTLMINER scores for candidate genes within the days 3-4 QTL 
interval (Chr 12): Traits 16334 and 16335. 
 
 Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score     
(1-4) 
Chromosome 12               
 
Sipa1l1 83.36 signal-
induced 
proliferation-
associated 1 
like 1 
regulation of synaptic 
plasticity,  regulation 
of small GTPase 
mediated signal 
transduction, 
regulation of dendrite 
morphogenesis 
3 7 Yes  4 
  
Ttc9 82.73 tetratricopepti
de repeat 
domain 9 
protein folding 38 3 Yes  4 
 
Smoc1 82.13 SPARC 
related 
modular 
calcium 
binding 1 
extracellular matrix 
organization, positive 
regulation of cell-
substrate adhesion 
18 15 No 3 
  
Acot2 85.33 acyl-CoA 
thioesterase 2 
lipid metabolic 
process,  acyl-CoA 
metabolic process, 
very-long-chain fatty 
acid catabolic process 
5 0 No 2 
 
Psen1 85.03 presenilin 1 regulation of resting 
membrane potential, 
negative regulation of 
neuron apoptosis, 
protein maturation by 
peptide bond cleavage, 
regulation of synaptic 
transmission, 
glutamatergic 
neurogenesis, skeletal 
system 
morphogenesis, T cell 
activation during 
immune response, 
brain morphogenesis, 
dorsal/ventral neural 
tube patterning, 
hemopoietic 
progenitor cell 
differentiation; 
myeloid leukocyte 
differentiation, 
endoplasmic 
reticulum, calcium ion 
homeostasis, Cajal-
Retzius cell 
differentiation, T cell 
receptor signaling 
pathway, thymus 
development, positive 
regulation of apoptosis 
0 1 No 2 
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Table 3-3.    (Continued). 
 
 Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score     
(1-4) 
Rbm25 84.97 RNA binding 
motif protein 
25 
apoptosis, RNA 
splicing, mRNA 
processing 
0 1 No 2 
Nek9 86.64 NIMA (never 
in mitosis 
gene a)-
related 
expressed 
kinase 9 
cell cycle, cell 
division, mitosis, 
protein amino acid 
phosphorylation 
2 0 No 2 
2410016O06R
ik 
85.29 RIKEN 
cDNA 
2410016O06 
gene 
transcription, 
oxidation reduction, 
regulation of 
transcription, 
chromatin 
remodeling, 
ribosome biogenesis, 
chromatin 
modification, 
negative regulation 
of osteoblast, 
differentiation, 
negative regulation 
of transcription, 
DNA-dependent, 
histone H3-K4 
demethylation, 
histone H3-K36 
demethylation 
1 0 No 2 
Zfyve1 84.89 zinc finger, 
FYVE 
domain 
containing 1 
biological process 1 0 No 2 
Rgs6 83.72 regulator of 
G-protein 
signaling 6 
signal transduction, 
negative regulation 
of signal 
transduction, 
intracellular 
signaling cascade 
G-protein coupled 
receptor protein 
signaling pathway 
positive regulation of 
neuron 
differentiation 
9 31 No 2 
Pcnx 82.96 pecanex 
homolog 
(Drosophila) 
biological process 
  
2 0 No 2 
Map3k9 82.83 mitogen-
activated 
protein kinase 
kinase kinase 
9 
protein amino acid 
phosphorylation, cell 
death 
positive regulation of 
apoptosis 
  
1 0 No 2 
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Table 3-3.    (Continued). 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score     
(1-4) 
  
Adam4 82.52 a disintegrin 
and 
metallopepti
dase domain 
4 
integrin-mediated 
signaling pathway 
  
3 0 No 2 
 
Synj2Bp 82.59 synaptojanin 
2 binding 
protein 
endocytosis, 
cytoplasm 
organization, protein 
targeting, Rho 
protein signal 
transduction, 
regulation of 
endocytosis, 
intracellular 
distribution of 
mitochondria 
3 0 No 2 
 
Tmed10 86.68 transmembra
ne emp24-
like 
trafficking 
protein 10 
(yeast) 
transport, vesicle-
mediated transport, 
protein transport 
intracellular protein 
transport, regulated 
secretory pathway, 
vesicle targeting, to, 
from or within Golgi 
  
1 0 No 2 
  
Ylpm1 86.34 YLP motif 
containing 1 
reduction of 
telomerase activity 
differentiation of 
embryonic stem cells 
2 0 No 2 
 
Jundm2 86.94 Jun 
dimerization 
protein 2 
transcription, 
regulation of 
transcription, DNA-
dependent, negative 
regulation of 
transcription from 
RNA polymerase II 
promoter 
  
1 0 No 2 
  
Rps6kl1 86.48 ribosomal 
protein S6 
kinase-like 1 
protein amino acid 
phosphorylation 
0 1 No 1 
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Table 3-3.    (Continued). 
 
 
Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score     
(1-4) 
 
Vsx2 85.91 visual system 
homeobox 2 
transcription, regulation 
of transcription, 
multicellular organismal 
development, DNA-
dependent positive 
regulation of cell 
proliferation, positive 
regulation of transcription 
from RNA polymerase II 
promoter, negative 
regulation of cell 
proliferation, cell fate 
commitment, retina 
morphogenesis in 
camera-type eye, retinal 
bipolar neuron 
differentiation, camera-
type eye development 
0 1 No 1 
  
Acot5 85.41 acyl-CoA 
thioesterase 5 
acyl-CoA metabolic 
process, lipid 
metabolic process, 
saturated 
monocarboxylic acid 
metabolic process, 
long-chain fatty acid 
metabolic process, 
very-long-chain fatty 
acid metabolic 
process, unsaturated 
monocarboxylic acid 
metabolic process 
2 0 No 1 
 
Acot3 85.39 acyl-CoA 
thioesterase 3 
lipid metabolic 
process, unsaturated 
monocarboxylic acid 
metabolic process, 
long-chain fatty acid 
metabolic process, 
very-long-chain fatty 
acid metabolic 
process, saturated 
monocarboxylic acid 
metabolic process, 
acyl-CoA metabolic 
process 
4 0 No 1 
  
Acot4 85.38 acyl-CoA 
thioesterase 4 
acyl-CoA metabolic 
process, succinyl-CoA 
metabolic process, 
lipid metabolic 
process, short-chain 
fatty acid metabolic 
process, dicarboxylic 
acid metabolic process 
1 0 No 1 
 
Tmem90a 86.02 transmembrane 
protein 90a 
response to biotic 
stimulus 
1 0 No 1 
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The H1N1 study identified a QTL on Chr 10 that was linked only with the day 1 
weight loss trait, and they concluded that much of the weight loss was transient and 
associated with the stress of anesthesia prior to intranasal instillation. Our findings 
support a similar conclusion for the day 1 weight loss trait. Although the QTLs identified 
in the two studies are on different chromosomes, this conclusion is feasible because our 
studies utilized inhaled isoflurane for anesthesia, while the studies by Nedelko et. al. used 
injectable anesthesia (ketamine/xylazine). Another stressor that could account for 
variation of the weight loss trait could be introduction of liquid vehicle (PBS) into the 
lungs during intranasal instillation. Again, the identification of loci on different 
chromosomes (Chrs 4 and 10) in our and the Nedelko et. al. studies, respectively, is 
feasible because instillation was performed with different volumes of vehicle (50μl vs. 
20μl, respectively). 
 
We used QTLminer to analyze these QTL intervals and to identify genes that are 
promising positional and biological candidate genes. Three candidate genes with high 
QTLminer scores were identified within the significant QTL on chromosome 12 that was 
observed on days 3 and 4 post-infection. One of these genes (Sipa1l1) encodes a protein 
that is thought to be involved in several processes that impact innate immunity: (1) 
positive regulation of RAP2A GTPase activity, (2) reorganization of the actin 
cytoskeleton and recruitment of DLG4 to F-actin, and (3) regulation of dendritic spine 
morphogenesis. Ttc9 is a hormonally regulated gene in breast cancer cells and may play a 
role in cancer cell invasion and metastasis [127]. The final candidate gene (Smoc1) 
encodes a putative regulator of osteoblast differentiation in bone marrow stromal cells 
[128] and plays a critical role in ocular and limb development in mice and humans 
through the modulation of BMP signaling [129, 130]. The heritability of the day 3 and 
day 4 weight loss traits approached 93%, indicating that these traits are likely to be 
genetically controlled. Moreover, principal component analysis revealed that the QTL on 
Chr 12 contributed >70% of the total weight loss variability in the cohort, indicating that 
a gene(s) within this interval is the most important genetic factor in weight loss kinetics. 
 
Although the loci that were identified on days 1 and 2 post-infection contribute 
30% or less to weight loss, we also examined them for gene candidates. There were four 
high value candidates associated with the day 1 Chr 4 locus. Car8 encodes a protein that 
is designated as carbonic anhydrase VIII, despite its lack of carbonic anhydrase activity. 
Mice carrying non-functional Car8 mutations suffer from neurological defects [131]. The 
Asph gene is expressed from two promoters and undergoes extensive alternative splicing, 
resulting in a set of aspartate beta-hydroxylases that have distinct functional properties.  
The longest isoform hydroxylates aspartic acid or asparagine residues in the epidermal 
growth factor-like domains of several proteins, including protein C, coagulation factors  
VII, IX, and X, and the complement factors C1R and C1S. ASPH is also thought to play 
an important role in calcium homeostasis [132]. Trp53inp1 encodes an antiproliferative 
and proapoptotic protein (tumor protein p53-inducible nuclear protein 1) that is involved 
in cell stress responses by acting as a dual regulator of transcription and autophagy [133-
135]. TRP53INP1 protein also reduces cell migration by regulating expression of 
SPARC, a regulator of cell growth through interactions with the extracellular matrix and 
cytokines. Inst8 encodes one component of a complex (integrator complex) that 
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associates with RNA polymerase II and is involved in the processing of small nuclear 
RNAs [136]. It remains unclear how any of the candidate genes within the Chr 4 interval 
might be involved in weight loss kinetics during the initial stages of melioidosis. 
 
There were several high-scoring candidate genes from the suggestive QTLs that 
were observed on day 2 post-infection. Lama5 (Chr 2) encodes a protein that is thought to 
mediate the attachment, migration and organization of cells into tissues during embryonic 
development. GtpBp5 (Chr 2) encodes a putative GTPase that may play a role in the 
regulation of processes such as protein synthesis, nuclear transport, membrane 
trafficking, and signal transduction [137, 138]. The gene product of Ss18l1 (Chr 2) is a 
transcriptional activator that is required for calcium-dependent dendritic growth and 
branching in cortical neurons. Psma7 (Chr 2) encodes a member of the peptidase T1A 
family that functions as a 20S core alpha proteasome subunit and participates in 
cytoplasmic protein degradation and recycling, while OsBpl2 encodes a member of the 
oxysterol-binding protein family of intracellular lipid receptors, known as oxysterol 
binding protein-like 2 [139]. Two of the high-priority candidate genes on chromosome 
17, Park2 and Pacrg, share a bidirectional promoter and are co-regulated in various 
tissues. Their gene products are involved in the degradation of misfolded or damaged 
proteins as well as in autophagy and mitophagy, and have a strong association with the 
development of Parkinson’s disease [140] [141, 142]. Interestingly, single nucleotide 
polymorphisms of Park2 and Pacrg are also associated with leprosy susceptibility in the 
Chinese population [143]. The other high scoring candidate gene on chromosome 17 was 
Qk, a gene that encodes an RNA-binding protein that plays a central role in myelination; 
dysfunction of this gene may result in myelin and/or oligodendrocyte dysfunction in 
schizophrenia [144]. It is difficult to predict the role of any of these genes in weight loss 
kinetics, but because the heritability of the Day 2 weight loss trait is approximately 87% 
(compared to 68.8% for the day 1 weight loss trait), it is much more likely that genes 
from one or both of these QTLs exert some control over weight loss during melioidosis. 
 
Our findings indicate that weight loss kinetics during acute pneumonic Bp 
infection is a heritable and dynamic trait that is controlled by several host loci in a time 
dependent fashion. A significant QTL on Chr 12 (between 80 and 87Mb) appears to be 
the most important genetic factor, while loci on chromosomes 2, 4, and 17 also contribute 
to weight loss. The strongest candidate genes are involved in processes that could be 
critical for immune processes, such as regulation of GTPase activity, reorganization of 
actin cytoskeleton, hydroxylation of coagulation factors and complement components, 
and autophagy. Several of the other strong candidates are involved in developmental 
processes that include osteoblast differentiation, regulation of cell growth and migration, 
tissue development during embryonic development, limb development, and myelination.  
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CHAPTER 4.    GENETICS OF DIFFERENTIAL SUSCEPTIBILITY TO 
PNEUMONIC BURKHOLDERIA PSEUDOMALLEI INFECTION 
 
 
INTRODUCTION 
 
In humans, infection with Bp can cause a rapidly developing acute form of 
melioidosis or there can be an extended latency period (that can last for many years) 
before the patient becomes symptomatic. In fact, Bp infection has been described as the 
“Vietnamese time bomb” due to reports that some US servicemen developed melioidosis 
up to six decades after their exposure to the bacterium in Vietnam [26, 145-147]. Humans 
and animals exhibit a broad range of clinical presentations following infection with Bp, 
but the host factors that contribute to the different forms of melioidosis remain unclear. 
Although no causal relationship has been determined, pre-existing host conditions in 
humans (such as renal dysfunction, diabetes mellitus, and alcoholism) are considered to 
be risk factors for the disease [7]. As previously mentioned, associations have been 
demonstrated between the clinical presentation of melioidosis and either the host’s HLA 
haplotype [49] or the allelic forms of some cytokine-related genes expressed by the host 
[50]. These findings suggest that host genetic factors determine (at least in part) the 
susceptibility of individual patients to the various clinical presentations of this disease. 
 
The murine infection model has been used to establish the importance of host 
genetic background on the progression of Bp infection, which is considered to be an 
excellent model for both the acute and chronic forms of human melioidosis [56, 60, 125]. 
BALB/c [56, 60] and D2 [61] mice are known to be extremely susceptible to the acute 
form of melioidosis, while B6 mice [56, 60] are relatively resistant to the acute form of 
the disease and instead tend to develop disease that progresses at a much slower rate. In 
this report, we have utilized a panel of BXD mice to perform genome-wide linkage 
analysis to identify host genetic loci that correlate with the differential susceptibilities of 
B6 and D2 parental strains to acute melioidosis. 
 
 
RESULTS 
 
 
Susceptibility of B6 and D2 Mice to Pneumonic Bp Infection 
 
As previously mentioned in Chapter 3, our initial studies with a pneumonic 
challenge model (intranasal instillation) confirmed the previously published observation 
[55, 61] that B6 mice are more resistant than D2 mice to Bp infection. We performed 
time course studies to kinetically evaluate the permissiveness of B6 vs. D2 mice to 
replication of Bp in vivo. We found that following intranasal instillation of 50-100 CFU 
of Bp strain 1026b, D2 mice experienced significantly higher (p?0.001) bacterial burdens 
in their lungs than B6 mice (see Figure 3-1A in Chapter 3). We also used survival as a 
readout to examine the relative susceptibility of B6 vs. D2 mice to pneumonic Bp 
infection. Following intranasal instillation with 50-100 CFU of Bp 1026b, we found that 
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D2 mice were significantly more susceptible to Bp infection than B6 mice (p?0.0001) as 
they succumbed to infection by day 4 post-infection, while B6 mice survived the 
infection (see Figure 3-1B in Chapter 3). Subsequent studies showed that the same 
results were obtained with challenge doses of up to 200 CFU/mouse (data not shown).  
 
 
Susceptibility of BXD RI Mice to Pneumonic Bp Infection 
 
To identify host genetic elements that are covariant with the variable 
susceptibility of murine hosts to pneumonic Bp infection, we initiated forward genetics 
studies with a cohort of BXD strains using survival of pneumonic infection as the 
phenotypic readout. Groups of male mice from 32 BXD strains were challenged with 50-
100 CFU of Bp 1026b (from a diluted frozen stock) via intranasal instillation and then 
monitored for survival. B6 and D2 mice were included in each of the 20 experiments that 
were performed, and the D2 mice were always the last group to be challenged to ensure 
the “potency” of the challenge stock throughout the instillation process. Strains that 
succumbed to acute melioidosis where given a score of “0” and mice that survived the 
challenge with Bp were given a score of “1”. We found that several of the BXD strains 
were highly susceptible to Bp (similar to D2 mice), others were relatively resistant to Bp 
(similar to B6 mice), and several strains displayed intermediate phenotypes           
(Figure 4-1A). 
 
 
Heritability of Survival and Time-to-Death 
 
Our data indicate that there are significant differences observed amongst the 
different BXD strains for survival and time-to-death. Since all mice used in this study 
were bred and housed in the same environment, it is likely that the observed differences 
in these phenotypes are mainly due to genetic variation. A heritability analysis 
summarizes how much of the variation in a trait is due to variation in genetic factors (as 
opposed to environmental or technical errors) and this value can range from 0 to 100%. 
The heritability of our survival and time-to-death trait was 71%, indicating that these 
traits are likely to be genetically controlled.   
 
 
Identification of Host Genetic Loci that Influence Survival Following Pneumonic Bp 
Infection 
 
Whole-genome linkage analysis of the survival phenotype using this cohort of 
animals revealed a significant QTL on chromosome 5 (genome-wide significance of 
0.015, LRS of 24.1 with D alleles contributing to increased survival) encompassing a 
region of approximately 12 megabases and a significant QTL on chromosome 7 
(genome-wide significance of 0.017, LRS of 23.5 with D alleles contributing to increased 
survival) encompassing a region of approximately 10 megabases that are both covariant 
with differential susceptibility/resistance to acute pneumonic melioidosis (Figure 4-1B). 
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Figure 4-1. Genome-wide linkage analysis of survival following pneumonic 
challenge with Burkholderia pseudomallei. 
   
A cohort of male mice, which included 32 BXD strains, was infected intranasally with 
50-100 CFU of Burkholderia pseudomallei.  Infected mice were monitored for survival 
for up to 11 days post-infection and those that survived infection were given a value of 
“1” while those that succumbed to infection received a value of “0”. Panel A: Log-Rank 
plot showing the mean± SEM of the survival value for each strain. Panels B and C: 
Standard and weighted interval mapping, respectively, was performed using the in silico 
resources within GeneNetwork.org to identify genetic loci that correlated with survival. 
The blue line indicates LRS scores across the entire genome. Thin red and green lines 
indicate that B6 or D2 alleles increase trait values, respectively. The mouse chromosomes 
are identified in the upper x-axis, the lower x-axis shows the physical map in mega bases 
for each chromosome, and the y-axis represents the LRS score. Thick red and grey 
horizontal lines indicate the genome-wide significance threshold (p<0.05) or suggestive 
threshold (p<0.63), respectively. 
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Intriguingly, these loci have an additive allele effect that does not correspond to 
expectation based on parental strain survival (D2 low, B6 high). Weighted QTL analysis 
of this dataset identified the loci on chromosomes 5 and 7 as highly significant QTLs 
(genome-wide significances of 0.011 and 0.009 with LRS scores of 161.7 and 175.9, 
respectively) (Figure 4-1C). The significant QTLs on chromosomes 5 and 7 were also 
identified when we used time-to-death of this BXD cohort as a phenotype for QTL 
analyses (Figure 4-2). It should be noted that further investigation of these two QTL 
regions using composite interval mapping and haplotype analyses revealed chromosomes 
5 and 7 are co-dependent because they exhibit the same pattern of inheritance. As a 
result, the QTL peak on chromosome 7 is more than likely to be an artifact (discussed in 
chapter 6).  
 
 
Identification of Candidate Host Genes that May Contribute to Host 
Susceptibility/Resistance Following Bp Infection  
 
The significant QTLs on chromosomes 5 and 7 each encompass regions of 
approximately 10-12 megabases that encode approximately 120 and 70 genes, 
respectively. We analyzed each of these loci to identify specific candidate genes within 
the QTL intervals whose function(s) might be important for the survival phenotype. For 
these candidate gene searches, we considered peak height and bootstrap analyses to 
define the QTL intervals (Figure 4-3). We then utilized the QTLminer tool [126] in 
GeneNetwork to identify genes within the QTL that are most likely to contribute to host 
susceptibility to pneumonic Bp infection. QTLminer scores genes on a scale of 0 to 4 
based on the following criteria: (1) the gene has a mRNA expression value ≥8 in the 
lungs in at least one of the expression databases provided on GeneNetwork, (2) the gene 
is cis-regulated in lung, (3) the gene contains at least 1 nonsynonymous SNP between the 
parental B6 and D2 mice, and (4) and the gene contains indels in BXD mice. The genes 
within each QTL that had the highest QTLminer score are listed in Figure 4-3 and in 
Table 4-1.  
 
 
Identification of Candidate Genes from Expression Profiling Using RNA-Seq 
 
Successful incorporation of RNA-Seq data with results of QTL mapping from an 
AIL can significantly reduce the number of positional candidates within the QTL 
region(s) [148]. We performed expression profiling on the lung tissue of 5 different BXD 
RI strains (3 mice/strain) infected with Bp 1026b for 24 hours. The resistant BXD strains 
used (BXD50 and BXD70) are the most resistant strains we have tested to date (100% 
survival with better weight retention when compared to B6 mice). The susceptible BXD 
strains used (BXD63, BXD09 and BXD27) had an average survival time of 4 days with 
100% mortality (similar to D2 mice).  Comparison of RNA expression between the 
resistant and susceptible mice identified many genes whose expression differed 
significantly. We used a stringent threshold of a ≥2-fold change and a p-value of ≤ 0.05 
for our analyses. Clustering based on functional characteristics between the resistant and 
susceptible strains revealed many of the upregulated genes in the resistant strains were  
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Figure 4-2. Genome-wide linkage analysis of the time-to-death trait following 
pneumonic challenge with Burkholderia pseudomallei. 
 
A cohort of male mice, which included 32 BXD strains, was infected intranasally with 
50-100 CFU of Burkholderia pseudomallei.  Infected mice were monitored for survival 
for up to 11 days post-infection. Mean survival time of each strain is shown in Panel A: 
Log-Rank plot showing the mean± SEM of the survival time for each strain. Panel B: 
Interval mapping was performed using the in silico resources within GeneNetwork.org to 
identify genetic loci that correlated with time-to death. The blue line indicates LRS scores 
across the entire genome. Thin red and green lines indicate that B6 or D2 alleles increase 
trait values, respectively. The mouse chromosomes are identified in the upper x-axis, the 
lower x-axis shows the physical map in mega bases for each chromosome, and the y-axis 
represents the LRS score. Thick red and grey horizontal lines indicate the genome-wide 
significance threshold (p<0.05) or suggestive threshold (p<0.63), respectively. 
genes on chromosomes 5 and 7 that may have some influence of the host response to 
pneumonic Bp infection.   
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Figure 4-3. Detailed maps of QTLs contributing to survival and candidate genes 
within these intervals.  
 
Left hand panels: The critical intervals were identified based on bootstrap analysis 
(frequencies of peak LRS indicated with yellow bars) and peak shapes. The density of 
SNPs present in the BXD strains is indicated by orange chatter along the x-axis. The 
multicolored chatter along the top of the graph represent the open reading frames within 
the interval. The blue line indicates LRS scores across the entire genome. Thin red and 
green lines indicate that B6 or D2 alleles increase trait values, respectively. The mouse 
chromosomes are identified in the upper x-axis, the lower x-axis shows the physical map 
in mega bases for each chromosome, and the y-axis represents the LRS score. Thick red 
and grey horizontal lines indicate the genome-wide significance threshold (p<0.05) or 
suggestive threshold (p<0.63), respectively. Right hand panels: Candidate genes within 
each interval are indicated along with their LRS score and their relative expression levels 
in normative tissues. 
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Table 4-1.    QTLMINER scores for candidate genes within the QTL interval for the 
survival trait (Chrs 5 and 7): Trait 16330. 
 
 Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score 
(1-4) 
Chromosome 5             
 Art3 92.76 ADP-
ribosyltransferas
e 3 
protein amino acid 
ADP-ribosylation 
103 10 Yes 4 
 Ankrd17 90.66 ankyrin repeat 
domain 17 
endoderm 
development 
20 11 Yes 4 
 G3Bp2 92.48 GTPase 
activating 
protein (SH3 
domain) binding 
protein 2 
transport, small 
GTPase mediated 
signal transduction, 
mRNA transport 
8 1 Yes 4 
 Asahl 92.69 N-
acylsphingosine 
amidohydrolase 
(acid 
ceramidase)-like 
lipid metabolic 
processes 
54 4 Yes 4 
 Anxa3 97.22 annexin A3 positive regulation of 
DNA metabolic 
processes 
7 8 Yes 4 
 Bmp2k 97.43 BMP-2-
inducible kinase 
protein amino acid 
phosphorylation, 
regulation of bone 
mineralization 
6 6 Yes 4 
 Cxcl9 92.75 chemokine (C-
X-C motif) 
ligand 9 
inflammatory 
responses, immune 
responses, cytokine-
cytokine receptor 
interaction, 
chemokine signaling 
pathway, toll-like 
receptor signaling 
pathway 
27 4 Yes 3 
 Areg 91.57 amphiregulin epidermal growth 
factor receptor 
signaling pathway, 
positive regulation of 
cell proliferation, 
glial cell 
proliferation, neuron 
projection 
development, 
positive regulation of 
phosphorylation, 
negative regulation of 
osteoblast 
differentiation, 
response to glucose, 
ErbB signaling 
pathway 
6 0 Yes 3 
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Table 4-1.    (Continued). 
 
 Gene   
Symbol 
Mb Gene 
Designation 
Biological 
Processes/Functions 
nsSNPs 
(B6 vs. 
D2) 
InDels 
in 
BXD 
Mice 
Cis-
Regulated 
in Lung 
QTL 
Miner 
Score 
(1-4) 
 Cox18 90.64 Cox18 
cytochrome c 
oxidase 
assembly 
homolog 
protein insertion into 
membrane 
15 0 Yes 3 
Chromosome 7 
 Ube3a 66.48 ubiquitin protein 
ligase E3A 
protein modification 
processes, protein 
ubiquitination, 
positive regulation of 
transcription from 
RNA polymerase II 
promoter, prostate 
gland growth, 
ubiquitin-dependent 
protein catabolic 
processes, positive 
regulation of 
phosphoinositide 3-
kinase cascade, 
sperm ent, Ubiquitin 
mediated proteolysis 
9 13 Yes 4 
 Atp10a 65.91 ATPase, class 
V, type 10A 
phospholipid 
transport, metabolic 
processes, ATP 
biosynthetic 
processes 
11 15 Yes 4 
 Tubgcp5 63.05 tubulin, gamma 
complex 
associated 
protein 5 
microtubule 
cytoskeleton 
organization 
13 8 Yes 4 
 Nipa1 63.23 non imprinted in 
Prader-
Willi/Angelman 
syndrome 1 
homolog 
transport, ion 
transport, magnesium 
ion transport 
3 2 Yes 4 
 Nav2 56.21 neuron 
navigator 2 
neuronal 
development, neurite 
outgrowth 
56 59 Yes 4 
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involved in processes such as immune response, defense response, regulation of 
apoptosis, and inflammatory response (Table A-2). The majority of the upregulated 
genes in the susceptible strains were involved in processes such as vesicle-mediated 
transport, membrane organization, defense response, and endocytosis (Table A-3).  
 
 
DISCUSSION 
 
It has been known for some time that distinct inbred strains of mice display a 
range of susceptibility to Bp infection. In this study, we employed a panel of recombinant 
inbred BXD genotypes to identify regions of the murine genome that are responsible for 
variable susceptibility to this bacterial pathogen. Since our trait is more than likely 
genetically controlled, we performed genome wide linkage analysis using survival and 
time-to-death following pneumonic infection with Bp 1026b to identify host genes 
involved in the differential progression of melioidosis. We identified two significant 
QTLs, one on chromosome 5 and the other on chromosome 7 that appear to be involved 
in the variability of susceptibility to pneumonic Bp infection. We utilized the in silico 
tools in GeneNetwork and global transcription data to identify candidate genes within 
each of these QTL intervals that are most likely to play a role in the outcome of Bp 
infection. 
 
Most of the high-priority candidate genes identified (using QTLminer) within the 
QTL on chromosome 5 appear to have a role in immunological processes. For instance, 
the cox18 gene encodes a mitochondrial inner membrane protein that is involved with 
cytochrome C assembly. It is known that a mutation of Cox18 results in deficient 
cytochrome C oxidase activity that, in turn, eliminates activation of cell surface receptors 
involved in apoptosis [149], a process that is essential for limiting replication of some 
intracellular bacterial pathogens [109, 150]. Another candidate gene in the interval, 
G3Bp2, encodes GTPase activating protein-binding protein 2. This protein is known to 
interact with IκB? and has been implicated in the regulation of NF-κB [151]. The NF-κB 
family of transcription factors is a group of evolutionarily conserved proteins involved in 
lymphoid organogenesis, development of immune cells [152] and the coordination of 
many aspects of innate and adaptive immunity to infection. Cxcl9 encodes a chemokine 
whose function(s) have not been clearly defined, but are likely to be important for T cell 
trafficking [153]. Art3 is one of five genes that encode a family of arginine-specific ADP-
ribosyltransferases, or ARTs. Arts 1 and 2 are known to play a role in the function of 
immune lymphocytes [154, 155]. ADP-ribosyltransferase activity has also been detected 
on the surface of both human neutrophils [156] and monocytes [157] and the activity of 
these enzymes is elevated in response to LPS treatment. Ankrd17 encodes a protein 
(ankyrin repeat protein 17) that participates in innate immunity by interacting with 
several intracellular molecules (RIG-I, MDA5, and VISA) that have a role in sensing the 
presence of diverse viral RNAs, resulting in positive regulation of RIG-I-like receptor-
mediated immune signaling [158]. Anxa3 encodes a protein that is known to have a role 
in bacterial phagocytosis [159], and as such is implicated as a component of the innate 
immune response. Asahl encodes an N-acylsphingosine amidohydrolase that catalyzes the 
synthesis and degradation of ceramide into sphingosine and fatty acid. Mutations in this 
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gene have been associated with a lysosomal storage disorder known as Farber’s disease 
[160]. This enzyme is involved in apoptosis pathways as well, but it is unclear whether it 
is directly involved in innate immunity. Amphiregulin (Areg) is a member of the 
epidermal growth factor family and has an important role in the immune response to 
nematode infection [161]. Finally, Bmp2k (the gene that encodes BMP-2-inducible 
kinase) is also found within this QTL. Bone morphogenic proteins (BMPs) have no 
known role in immune responses, but they are known to play a key role in skeletal 
development and patterning [162] and have been implicated in lung development, and 
adult lung homeostasis [163].  
 
Only one of the candidate genes with the highest correlation indices within the 
QTL on chromosome 7 (Ube3a, Tubgcp5, Nipa1, and Nav2) have an obvious role in host 
innate immune responses. Ube3a encodes E3 ubiquitin-protein ligase, part of the 
ubiquitin protein degradation system [164]. Although this process is critical for antigen 
presentation to T cells, it likely has no role in innate immune responses. Tubgcp5 encodes 
a protein (gamma complex-associated protein 5) that has essential roles in mitotic spindle 
formation [165, 166] and microtubule nucleation and organization [165, 167]. Nipa1 
encodes a protein that plays a role in nervous system development and maintenance 
[168], and may function as a receptor or magnesium transporter [169], and Nav2 encodes 
neuron navigator 2, a protein involved in neuronal development, but that likely has no 
direct role in innate immunity. However, Atp10a encodes a P-type cation transport 
ATPase that could have an important role in disease susceptibility. In a recent 
transcriptomic study designed to identify genetic markers that can differentiate between 
individuals that experience either acute vs. latent Mycobacterium tuberculosis (MTB), 
Atp10a was one of three genes (along with Cxcl10 and Tlr6) whose expression levels 
were discriminatory. It remains to be determined whether Atp10a 
expression/functionality is responsible for variable susceptibility to MTB.  
 
We went further and cross-referenced candidate genes generated from QTLminer 
with our RNA-Seq expression data. We checked for genes that fell within our suggestive 
and/or significant QTL regions for our weight loss (chromosome 4, 7-11 mb, 
chromosome 2, 179.25-180 mb, and chromosome 17, 9.5-11.5 mb) and survival 
(chromosome 5, 85-98 mb and chromosome 7, 56- 67 mb). This analysis found a few 
compelling genes that fell within two of our QTL intervals (chromosomes 5 and 7). 
Genes that were significantly upregulated in the resistant strains include the closely 
related interferon-gamma inducible genes, Cxcl9, Cxcl10, and Cxcl11, that encode the 
chemokine (C-X-C motif) ligands 9, 10, and 11, respectively; and Ndn, which encodes 
the protein necdin. These genes exhibited a Bp-infection state fold change of 10, 9, 24, 
and 4, respectively. Specifically, in humans, Cxcl9 , Cxcl10 and Cxcl11 are inflammatory 
chemokines that mediate the recruitment of T cells, natural killer cells and 
monocytes/macrophages at the site of infection [170]. These chemokines exert their 
effects through their cognate G-protein coupled receptor, CXCR3 [170, 171]. Ndn is 
located in the Prader-Willi Syndrome deletion region and encodes a growth suppressor 
(necdin) that facilitates the entry of the cell into cell cycle arrest and inhibits cell growth 
[172]. Furthermore, necdin has been called a multi-functional protein with a potential role 
in tumor suppression [173].  
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Next, we organized these candidate genes into cis eQTLs and trans eQTLs based 
on the genomic location of the gene of origin. Cis eQTLs map to the same genomic 
location as the expressed gene [174] and therefore exerts a direct effect on its function. 
Conversely, trans eQTLs also known as distant eQTLs, map far away from the location 
of the expressed gene and therefore has a secondary effect on the trait [77]. Cxcl9, Cxcl11 
and Ndn are all cis eQTLs and are high priority genes for future validation studies to 
completely examine their role in the resistance and/or susceptibility to Bp infection.  
 
We performed this same cross-reference analysis with genes that were 
significantly upregulated in the susceptible strains and fell within all of our suggestive 
and/or significant QTL regions. Similar to the previous analysis, this approach did not 
identify any genes within the weight loss QTL intervals. However, there were five 
candidate genes found within our survival QTLs (on chromosomes 5 and 7) when cross-
referenced with our expression data. They include, Fam47e (family with sequence 
similarity 47), whose function has yet to be confirmed, but some reports describe it as 
having transcription cofactor activity [175]. Prdm8 (protein domain containing 8) which 
may play a role in chromatin binding, cell morphology and cytoskeletal organization 
[176]. Chrna7 encodes the neuronal acetylcholine receptor subunit alpha-7, a cholinergic 
receptor that mediates fast signal transmission at synapses and is a member of a 
superfamily of ligand-gated ion channels [177]. Interestingly, this gene is located in a 
major susceptibility locus for juvenile myoclonic epilepsy [178] and is near a 
chromosomal location involved in the genetic transmission of schizophrenia [179]. Other 
genes include, Snrpa1, which encodes the small nuclear ribonuclearprotein polypeptide 
that function in mRNA processing by binding to RNA and cell cycle regulators [180]. 
Finally, Tm2d3 encodes TM2 domain containing 3, which may have functional roles in 
cell death or cell proliferation signalling cascades [181]. Chrna7 is the only cis eQTL 
from this group of candidate genes identified from our expression data. Infection state 
differences of these genes ranged from two- to sevenfold in the susceptible mice. In sum, 
only ~5% of differentially expressed genes from our expression profiling data reside 
within our survival/weight loss QTL regions. This observation calls into question the role 
of the remaining differentially expressed genes corresponding to survival of Bp infection. 
These genes may have a contributing role to survival during a Bp infection, although this 
point is merely speculation. It would be interesting to evaluate whether we observe 
alternate gene expression changes in various tissues and at different times points, which 
may help in understanding some of the relationships in gene expression patterns during a 
Bp infection.  
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CHAPTER 5.    EFFICIENT INACTIVATION OF BURKHOLDERIA 
PSEUDOMALLEI OR FRANCISELLA TULARENSIS IN INFECTED CELLS FOR 
SAFE REMOVAL FROM BIOSAFETY LEVEL 3 CONTAINMENT 
LABORATORIES* 
 
 
CHAPTER SUMMARY 
 
Working with infectious agents that require BSL-3 level containment offers many 
challenges for researchers. BSL-3 containment laboratories are usually not equipped with 
expensive specialty equipment that is needed for studies such as flow cytometric analysis, 
microscopy, and proteomic analyses. Therefore, for most researchers that are working 
with BSL-3 level infectious agents, removal of samples from BSL-3 labs for these types 
of studies is necessary, and methods for complete and dependable inactivation of the 
samples are required. In this report, we carried out a thorough characterization of the 
effectiveness of paraformaldehyde fixation for inactivation of cell samples infected with 
the intracellular bacterial agents Burkholderia pseudomallei (Bp) and Francisella 
tularensis (Ft), both of which are Tier 1 select agent pathogens that require BSL-3 
containment. We have demonstrated that cells infected with these pathogens are 
completely inactivated via 5-minute treatment with 4% paraformaldehyde. Moreover, a 
15-minute treatment with 2% paraformaldehyde completely sterilized both Bp- and Ft-
infected cells. These studies also revealed that Bp is significantly more sensitive to 
paraformaldehyde treatment than Ft. Our findings have clearly demonstrated that a 15-
minute treatment of Bp- or Ft-infected cells with 4% paraformaldehyde solution will 
allow for safe removal of the cell samples from BSL-3 labs for downstream studies. 
 
 
INTRODUCTION 
 
Flow cytometry has become an integral tool for the evaluation of immune 
responses to various cells during an infection with viral or bacterial agents.  Due to the 
expense of this type of equipment and the technical expertise required for proper 
operation, flow cytometers/cell sorters are typically found in shared core facilities that 
employ dedicated operators for analysis of a variety of sample types.  This creates many 
challenges for researchers working with agents requiring biosafety level 3 (BSL-3) 
containment, since most core flow cytometry facilities are located in laboratories with 
biosafety level 2 (BSL-2) containment capabilities.  Additional factors such as 
biosecurity play a role when the agents in use are considered select agents, and these 
security procedures must be maintained until the samples are rendered noninfectious. 
                                                 
 
*Reprinted with permission.  Emery, F.D., J.M. Stabenow, and M.A. Miller, Efficient    
inactivation of Burkholderia pseudomallei or Francisella tularensis in infected cells for 
safe removal from biosafety level 3 containment laboratories. Pathogens and disease, 
2014. 71(2): p. 276-81. 
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Removal of BSL-3 agents to a lower containment level laboratory requires 
inactivation of the pathogen to allow for safe manipulation of the sample, and to ensure 
that biosafety considerations are met for personnel working with these samples [182]. 
This is of particular concern when dealing with BSL-3 select agents destined for flow 
cytometric analysis, where the potential for generation of aerosols exists.  While 
biosafety standards have been well described for work with unfixed cells for cell sorting 
procedures, little guidance can be found for effective inactivation procedures for 
potentially infectious flow cytometry samples [183, 184].  Previous studies have shown 
that samples containing high titers of known viruses were resistant to standard 
inactivation procedures [185, 186]. These findings have been cited by the International 
Society for Analytical Cytology (ISAC), which cautions that fixation procedures must be 
carefully performed to ensure complete inactivation of any potential infectious agents to 
reduce the health risk to laboratory personnel [187, 188].  The ISAC also recommends 
that if samples are fixed, “appropriate methods must be selected to reliably inactivate 
potentially biohazardous agents,” yet no specific methods are recommended [187]. 
 
Most fixation procedures for flow cytometry include the use of paraformaldehyde 
(PFA) solutions at concentrations varying from 1-4%.  Commercially available fixation 
buffers are typically comprised of a neutral pH-buffered saline solution with 4% (w/v) 
PFA. These methods have been shown to provide effective fixation of lymphoid cells, 
following immunofluorescent staining of surface markers or intracellular cytokines, that 
is compatible with flow cytometric analysis (BD Technical Data Sheet, BD Cytofix TM). 
However, the ability of these compounds to provide for inactivation of potentially 
infectious microorganisms has been focused primarily on clinical samples with low levels 
of organisms present, and the incubation time for complete inactivation of potentially 
infectious agents has not been established.  Here we evaluate the PFA concentration and 
incubation time required to completely inactivate Francisella tularensis and 
Burkholderia pseudomallei within infected cells. Both of these agents are classified as 
Tier 1 select agents and require BSL-3 containment.  We have validated the inactivation 
kinetics required to demonstrate complete inactivation of these bacteria to allow for 
removal of samples from a BSL-3 laboratory for flow cytometric analysis using BSL-2 
containment practices.  
 
 
MATERIALS AND METHODS 
 
 
Collection and Differentiation of Murine Bone Marrow Cells 
 
Bone marrow cells were obtained aseptically from femurs and tibias of 9-12 week 
old C57BL/6J mice using previously described methods [189] and cryogenically stored at 
-80˚C in freezing medium (DMEM [ScienceCell, Carlsbad, Ca.] with 50% FCS [Sigma 
Chemical Co., St. Louis, MO] and 10% DMSO [Sigma Chemical Co., St. Louis, MO]). 
Frozen bone marrow cells were thawed and differentiated into BMDMs using culture 
conditions that were established previously [190].  Briefly, after thawing cells were 
pelleted via centrifugation (200 x g for 5 minutes at RT˚), resuspended in 10 mL bone 
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marrow differentiation media (D20/30: DMEM supplemented with 20% FBS, 30% L-929 
conditioned medium [LCCM], penicillin/streptomycin [100U/mL and 100mg/mL, 
respectively, Cellgro, Manassas, VA], 2mM L-glutamine [Cellgro, Manassas, VA] and 
50mg/mL gentamycin [Sigma, St. Louis, MO]), and seeded in 100-mm-diameter tissue 
culture dishes (BD Biosciences, San Jose, CA). The cultures were incubated at 37°C in a 
5% CO2 atmosphere for four days and then10mL of fresh D20/30 was added and 
incubated for an additional 3 days to allow cells to adhere to the petri dish. To harvest the 
BMDM, culture media was removed via aspiration and 10mL of cold 0.53mM 
EDTA/PBS was added to the plate and incubated at 37°C for 15 minutes.  The BMDM 
were detached by gently pipetting the PBS across the dish several times.  The BMDM 
cell suspension was pelleted via centrifugation (200 x g for 5 minutes at RT˚) then 
resuspended in BMDM cultivation media (D10/5:  DMEM supplemented with 10% FBS, 
5% LCCM, 2mM L-glutamine).  The cells were then counted using a Scepter 2.0 
Handheld Automated Cell Counter (EMD Millipore, Billerica, MA).   
 
 
Bacteria 
 
Burkholderia pseudomallei, strain 1026b (Bp) was obtained from Biodefense and 
Emerging Infections Research Resources Repository (BEI Resources, Manassas, VA) 
and Francisella tularensis tularensis, Schu S4 strain (Ft) was obtained from the Centers 
for Disease Control and Prevention (CDC, Atlanta, GA). Overnight cultures of both 
bacterial agents were prepared and used to inoculate fresh media. Once the bacteria 
reached log-phase growth, they were pelleted by centrifugation, resuspended in the 
appropriate media (see below) supplemented with 20% glycerol, aliquoted 
(approximately 100μl/tube), and stored cryogenically at -80˚C. Bp was cultured in 
unmodified LB broth and Ft was cultured in modified Mueller Hinton broth (MMH broth 
supplemented with 10 g/L tryptone, 0.1% glucose, 0.025% ferrous pyrophosphate, 0.1% 
L-cysteine, and 2.5% calf serum). Enumeration of these frozen stocks was performed by 
dilution plating as described below. All work with these two bacterial agents was 
performed under BSL-3 containment using standard operating procedures that were 
reviewed and approved by the University of Tennessee Health Science Center (UTHSC) 
Institutional Biosafety Committee (IBC). All BSL-3 laboratories in the RBL are 
registered with the select agent Program and all of the work with the select agents was 
done in a Centers for Disease Control (CDC)-approved facility (UTHSC Regional 
Biocontainment Laboratory, CDC Registration Number: C20010616-1230).  
 
 
Infection of Cells with Bp or Ft  
 
BMDM were seeded into a 150-mm-diameter non-tissue culture dishes (Sarstedt, 
Newton, NC) at a density of approximately 5 x 10e7 cells per plate and the bacteria 
(thawed from frozen stocks and diluted) were added to each plate at an MOI of 100. Cell 
cultures were allowed to incubate for approximately 12-15 hours after infection. After the 
incubation period, the media was carefully aspirated from the cell monolayers and 10mL 
of 0.53mM EDTA/PBS was added to each petri dish and allowed to incubate at 37°C for 
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15 minutes. The macrophages were then detached by gently pipetting across the dish 
several times.  The infected cells were pelleted via centrifugation (200x g for 5 min @ 
RT˚), washed twice with DMEM-20 (DMEM supplemented with 20% FBS), and then 
washed in culture medium containing kanamycin to kill remaining extracellular bacteria.  
Cells were washed two additional times with PBS. The cells were then resuspended in 10 
mL BD-Staining Buffer and then the cells were enumerated using a Scepter Handheld 
Automated Cell Counter.   
 
 
Fixation of Infected Cells  
 
Bp- or Ft-infected cells were distributed into Eppendorf® tubes at approximately 
1X106 cells/tube. The cells were pelleted via centrifugation (300x g at 4°C for 5 min) and 
then supernatant was aspirated. Cells were then treated with 250μl BD-Cytofix Fixation 
Buffer (Cytofix, BD Biosciences, cat.no. 554655, San Jose, CA) in undiluted form 
(4.21% PFA solution), diluted 1:2 (2.1% PFA solution), diluted 1:4 (1% PFA solution), 
or diluted 1:8 (0.5% PFA solution) and incubated for the indicated periods of time. 
Dilutions of Cytofix were performed using BD Pharmingen Stain Buffer (Stain Buffer, 
BD Biosciences, cat.no. 554655, San Jose, CA). Following the fixation incubation period, 
the total volume of each sample was increased to 1 ml by addition of Stain Buffer, the 
cells were pelleted via centrifugation (200 x g for 5 min at RT˚), supernatant was 
aspirated, and the cells were resuspended in 1 ml of Stain Buffer. 
 
 
Enumeration of Bacteria  
 
At each of the indicated time points following Cytofix treatment, suspensions of 
Bp- or Ft-infected cells that had been treated with Cytofix were subjected to dilution 
plating, as previously described [108, 109], to enumerate the remaining viable Bp or Ft in 
the sample. Briefly, the cell suspensions were plated in duplicate (100 μl of the fixed cell 
preparation per plate) on either LB agar (Bp) or BHI agar (Ft) plates using an Eddy Jet 
spiral plater (Neutec Group, Inc., Farmingdale, NY). Plates were incubated at 37˚C in a 
static incubator for 24-48 hours and then colonies were counted using a Flash & Go 
automated colony counter (Neutec Group, Inc., Farmingdale, NY) to determine the 
bacterial burdens (CFU/mL). 
 
 
RESULTS 
 
To evaluate the ability of PFA to kill the intracellular bacterial pathogens 
Burkholderia pseudomallei (Bp) strain 1026b and Francisella tularensis tularensis (Ft) 
strain Schu S4 during fixation of infected cells, we performed time course studies in 
which infected murine macrophages were treated with a range of concentrations of 
paraformaldehyde solution (0.5-4%). Murine BMDMs were infected with each of the 
pathogens at an MOI of 100 and cultured for 12-15 hrs to allow bacterial replication in 
infected cells. After the cells were harvested, washed and enumerated, they were 
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distributed into O-ringed centrifuge tubes (5 x 105 cells/tube) and pelleted via 
centrifugation, supernatant aspirated away, and then the cells were resuspended in PFA 
solution (0.5, 1.0, 2.1, or 4.21%). Dilution plating was performed at each treatment time 
point (1, 5, 10, 15, 30, and 45 minutes as well as 1, 4, 8, and 24 hrs) to determine how 
many viable bacteria remained in each fixed cell sample (Table 5-1 and Table 5-2). A 5-
minute treatment with BD-Cytofix (4.21% paraformaldehyde) killed all Bp              
(Figure 5-1A) and Ft (Figure 5-1B), while 2.1% PFA treatment required 15 minutes to 
completely sterilize the infected cell samples. Treatment with 1% or 0.5% 
paraformaldehyde failed to completely sterilize infected cell samples even after a 24-hour 
treatment period (Figure 5-1, Table 5-1 and Table 5-2).  
 
Because the lower detection limit of the dilution plating method is approximately 
20 CFU, we performed parallel experiments in which PFA-treated samples of infected 
cells were added to 10 mL of broth culture medium (LB broth for Bp-infected cell 
cultures and MH broth for Ft-infected cells) and incubated at 37˚C for 72 hours in a 
shaking incubator. Optical density readings (OD@ 600nm) taken prior to and following 
incubation to confirm that treatment for 5 minutes (or more) with 4% PFA or for 15 
minutes (or more) with 2% PFA completely sterilized samples of Bp- or Ft-infected cells 
(data not shown).  
 
Analysis of the data generated for the 1% and 2.1% paraformaldehyde treatment 
groups revealed that Bp is significantly more sensitive to paraformaldehyde treatment 
than Ft (Figure 5-2). Over the treatment time course, the burden of viable Bp following 
treatment with 1% and 2.1% paraformaldehyde solution was significantly lower than that 
of Ft (p<0.0001 and p<0.0039, respectively). Moreover, although the reduction of viable 
Ft was slightly greater than that of Bp following 15 minute treatment with 0.5% 
paraformaldehyde, Bp was much more sensitive to treatment with higher concentrations 
of paraformaldehyde solution (Table 5-3 and Table 5-4). For instance, a 15-minute 
treatment with 1% paraformaldehyde resulted in a 6.6±1.72-fold reduction of viable Bp 
numbers compared to only a 0.97±0.22 fold reduction of viable Ft. A 10-minute 
treatment with 2.1% paraformaldehyde resulted in a 260.6±149.8-fold reduction of viable 
Bp but only a 4.57±0.69-fold reduction of viable Ft, while a 1-minute treatment with 
4.21% paraformaldehyde solution resulted in a 1555±865.7-fold reduction of viable Bp 
numbers but only a 35.2±5.01-fold reduction of viable Ft numbers  
(Table 5-3 and Table 5-4). 
 
 
DISCUSSION 
 
The BMBL clearly states that removal of research samples from BSL-3 
containment for downstream studies (e.g. flow cytometric analysis, microscopy, 
proteomic analyses, etc.) at lower biosafety levels requires reliable standard operating 
procedures (SOPs) for complete infectious agent inactivation [191]. Although one could 
reasonably assume that standard fixation or other inactivation procedures involving 
various chemical agents would effectively inactivate most organisms, validation of the 
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Table 5-1.    Number of Burkholderia pseudomallei following paraformaldehyde 
fixation of infected cell samples (1st 15 minutes of timecourse). 
 
Treatment 1 Minute 5 Minutes 10 Minutes 15 Minutes 
Untreated 
 
119,333±14,224 113,333±5,686 99,567±2,676 94,700±985 
0.5% PFA 
 
91,900±7,539 84,800±200 81,267±2,098 79,233±3,355 
1.0% PFA 
 
52,967±3,742 37,967±4,438 35,133±4,329 12,900±2,946 
2.1% PFA 
 
42,667±907 12,230±8,128 538±419 0 
4.2% PFA 
 
89±33 0 0 0 
 
PFA- paraformaldehyde 
 
 
 
 
Table 5-2.    Number of Francisella tularensis following paraformaldehyde fixation 
of infected cell samples (1st 15 minutes of timecourse). 
 
 
PFA- paraformaldehyde 
Treatment 1 Minute 5 Minutes 10 Minutes 15 Minutes 
Untreated 
 
4,437±325 4,290±251 4,433±125 4,517±278 
0.5% PFA 
 
4,290±251 4,320±375 3,663±134 3,483±672 
1.0% PFA 
 
2,783±50 1,940±251 1,810±26 1,753±57 
2.1% PFA 
 
1,983±533 1,427±93 890±15 0 
4.2% PFA 
 
141±32 0 0 0 
  54 
 
 
 
Figure 5-1.    Paraformaldehyde fixation conditions for killing of Burkholderia 
pseudomallei and Francisella tularensis Schu S4 in infected cell samples. 
 
Murine BMDMs infected with (Panel A) Burkholderia pseudomallei 1026b or (Panel B) 
Francisella tularensis Schu S4 (5 x 106 cells/sample) were treated with the indicated 
concentrations of paraformaldehyde for either 1, 5, 10, 15, 30, or 45 min and 1, 4, 8, and 
24 hrs. At the end of the treatment period live bacteria were enumerated by dilution 
plating. All data points represent the mean ± SEM of triplicate samples. Statistical 
analysis was performed using a 2-way ANOVA and revealed that each of the PFA 
treatments resulted in significant reduction of viable bacteria compared to untreated 
controls (*** indicates p<0.001). The results shown are representative of three separate 
experiments of similar design.  
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Figure 5-2.    Burkholderia psuedomallei is more sensitive than Francisella tularensis 
to paraformaldehyde treatment. 
 
Murine BMDMs infected with either B. pseudomallei or F. tularensis were treated with 
the indicated concentrations of paraformaldehyde for either 1, 5, 10, 15, 30, or 45 min 
and 1, 4, 8, and 24 hrs and then surviving bacteria were enumerated via dilution plating. 
Data points represent the percentage of the starting number of CFU (untreated control 
sample at that time point) that survived paraformaldehyde treatment and are presented as 
the mean ± SEM of results with triplicate samples. Statistical analysis was performed 
using a 2-way ANOVA and the indicated p-values reflect differences attributable to the 
bacterium over the time course. Bonferroni posttests were also performed and significant 
differences at each time point are indicated (*** indicates p<0.001). The results shown 
are representative of three separate experiments of similar design. 
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Table 5-3.    Fold reduction of viable Burkholderia pseudomallei following 
paraformaldehyde fixation of infected cell samples. 
 
Treatment 1 Minute 5 Minutes 10 Minutes 15 Minutes 
0.5% PFA 
 
0.31±0.023 0.34±0.07 0.23±0.04 0.20±0.06 
1.0% PFA 
 
1.27±0.41 2.0±0.27 1.87±0.39 6.60±1.72 
2.1% PFA 
 
1.80±0.39 15.95±17.4 260.6±149.8 - 
4.2% PFA 1555±865.7 - - - 
 
 
PFA- paraformaldehyde 
 
 
 
 
Table 5-4.    Fold reduction of viable Francisella tularensis following 
paraformaldehyde fixation of infected cell samples. 
 
Treatment 1 Minute 5 Minutes 10 Minutes 15 Minutes 
0.5% PFA 
 
0.04±0.08 0.25±0.11 0.35±0.05 0.38±0.06 
1.0% PFA 
 
0.34±0.07 0.50±0.13 0.9±0.24 0.97±0.22 
2.1% PFA 
 
0.89±0.37 1.62±0.32 4.57±0.69 - 
4.2% PFA 35.2±5.01 - - - 
 
 
PFA- paraformaldehyde 
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method is required with each infectious agent to satisfy these requirements.  Moreover, 
the selected method for deactivation must also be compatible with the downstream 
analyses that will be performed on the inactivated sample. The use of published 
inactivation methods must also be validated for each laboratory to ensure that the 
procedures are followed correctly and complete inactivation can be achieved.  The lack of 
standardized protocols, including the kinetics of the methods, is problematic to 
researchers working with BSL-3 agents and often requires development of methods that 
meet the inactivation requirement while maintaining the integrity of the sample matrix for 
subsequent analysis. 
 
There are a variety of published studies that detail inactivation techniques for 
Francisella tularensis. A study by Clemens and associates described the use of 4% PFA 
in PBS overnight as an effective treatment for inactivation of Ft [192]. A different group 
successfully utilized three different treatments (2% PFA for 1 hr, heat-inactivation at 
60˚C for 16 hrs, or UV irradiation [7,500μJ/cm3 at RT˚]) to inactivate Ft [193]. Other 
published studies reported that Ft is susceptible to heat-inactivation [194, 195] or that 
inanimate surfaces contaminated with Ft can be sterilized by a combination of 10% 
bleach treatment followed by 70% ethanol [196]. However, in each of these reports the 
inactivation treatment was performed on bacteria alone, not on infected cells. Moreover, 
among these inactivation methods, only PFA treatment is compatible with any of the 
potential downstream analyses of infected cells. There is one published report that 
described inactivation of Ft-infected cells using 3-8 % PFA treatment for 30 minutes 
[197]. However, this paper does not contain any primary data related to the efficacy of 
PFA inactivation, but instead only cites guidance from a 2006 CDC website report that is 
no longer available.  
 
There is also a paucity of published information relating to the inactivation of 
Burkholderia pseudomallei. One published study showed that Bp in liquid samples could 
be inactivated by treatment with a combination of pH, heat, and salinity [198]. Another 
report revealed that Bp on environmental surfaces could be inactivated by treatment for 
15 minutes with 6% PFA [199]. O’Connell and colleagues have published studies 
designed to evaluate the effectiveness of chlorine-based disinfection (in water treatment 
systems) for inactivation of Bp [200]. One of the most interesting findings in this report 
related to the significant variability observed in the sensitivity of different Bp strains to 
chlorine-based disinfection. These findings reinforced the idea that inactivation methods 
should be validated for each infectious agent. We have been unable to find any published 
studies that define inactivation parameters for Bp-infected cells that would be compatible 
with downstream flow cytometric analysis. 
 
The findings provided in this report are the first that clearly establish a procedure 
that can be used to reliably and completely disinfect mammalian cells that have been 
infected with the BSL-3 agents Ft and Bp, allowing for their removal from BSL-3 
containment for downstream flow cytometric analyses using BSL-2 practices. 
Paraformaldehyde treatment was chosen for the current studies because: (1) is the most 
commonly used fixation treatment for flow cytometry samples, (2) it is known to have 
negligible effects on fluorescence properties or forward scatter/side scatter characteristics 
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of antibody labeled cells (Lal, et al., 1988), and (3) because there are commercial 
sourcesof paraformaldehyde solutions that are designed specifically for fixation of cells 
for flow cytometric analysis. Here we report that fixation for 5 minutes with a 4.21% 
PFA solution is capable of complete sterilization of cell suspensions that have been 
infected with either Ft or Bp. Moreover, a 15-minute treatment of Ft or Bp-infected cells 
with a 2.1% PFA solution results in complete inactivation of the sample. Our findings 
also indicated that treatment of either Ft- or Bp-infected cells with concentrations of PFA 
that are lower than 2.1% (1% and 0.5 %) is likely to result in incomplete disinfection of 
the samples. Based on these findings, we conclude that a 15 minute treatment of Ft- or 
Bp-infected mammalian cells with 4.21% paraformaldehyde is an appropriate SOP for 
inactivation of these two infectious agents, allowing for removal of fixed cells samples 
from BSL-3 containment. Interestingly, we also found that Bp is significantly more 
sensitive than Ft to PFA treatment. Although this finding did not impact the 
establishment of the inactivation SOP, it did provide further evidence that infectious 
agents display a range of sensitivities to chemical inactivation, underscoring the need for 
independent testing and validation of inactivation SOPs for each agent. It is important to 
note that these studies were performed exclusively on single cell suspensions of Bp or Ft 
infected cells. It is likely that sterilization of Bp or Ft-infected tissues (that have not been 
homogenized into single cell suspensions) would require longer exposure times than 
those described in this report. 
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CHAPTER 6.    DISCUSSION AND CONCLUSIONS 
 
 
DISCUSSION 
 
Bp is the cause of the frequently fatal infectious disease melioidosis. Little is 
known about the influence of specific genes or genetic backgrounds in humans that 
contribute to the susceptibility or resistance to Bp infections. Therefore, the identification 
of key host genetic factors that control resistance or susceptibility to Bp is of much 
importance. For these studies, we used a forward genetics approach to identify genomic 
regions influencing infection-state phenotypes seen during a Bp infection. The results 
from our studies demonstrate that the BXD RI strain panel and the GeneNetwork 
Database are powerful genetic resources for analyzing the differential susceptibility to a 
Bp infection. It has shown to be an efficient methodology which to examine infectious 
disease susceptibility genes in a host utilizing an expanded set of RI strains. To our 
knowledge, this study is the first report that uses a forward genetics approach to discover 
genes that underlie resistance and/or susceptibility to this pathogen.  
 
Our data indicate that genetic regulation of survival, time-to-death and weight loss 
during a Bp infection is a complex phenomenon, whereby many genes exert their effects 
on these traits. We observed significant differences in survival, time-to-death and weight 
loss kinetics in the parental mice and across the different BXD strains following 
pneumonic infection with Bp 1026b. This observed variability was expected based on the 
genetic diversity of the parental mice and the BXD strain family. We hypothesize that the 
observed differences in weight loss kinetics and survival amongst these strains can be 
attributed to the genetic variation resulting in varying levels of qualitative and 
quantitative profiles of the host defense. Furthermore, our heritability analyses for these 
phenotypes indicate there is a major influence of genetic background to these traits.  
 
Genome wide linkage analysis using these phenotypes identified several host loci 
associated with the observed differential response to Bp, and it is apparent that these traits 
are likely controlled by several loci encompassing many genes. According to our linkage 
analysis, weight retention during a Bp infection is controlled by QTLs on chromosomes 
2, 4, 12, and 17 in a time-dependent manner. This indicates that host loci within these 
QTLs may be important for the host response in a transient and dynamic fashion during 
melioidosis. However, a principle component analysis for weight loss at all days supports 
a single chromosomal locus on chromosome 12 that accounts for >70% of the total 
weight loss variability in the cohort. This means that loci identified on days 1 and 2 
contribute 30% or less to the variation in weight loss kinetics indicating chromosome 12 
is likely to be the single primary factor responsible for differential weight loss following 
Bp infection. Interestingly, a recently reported genome wide study of host response to 
H1N1 influenza infection also identified multiple QTLs (different from those identified 
here) that appear to control weight loss kinetics in a time-dependent fashion [73]. This 
study concluded that much of the initial weight loss was transient and associated with the 
stress of anesthesia prior to intranasal instillation. Meanwhile, our genome wide linkage 
analysis of survival (and time-to-death) generated two significant QTLs, one on 
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chromosome 5 and the other on chromosome 7. It is worth noting that the lack of overlap 
in loci contributing to survival compared to weight loss kinetics suggested that the weight 
loss and survival traits are independently controlled. A network diagram generated using 
the Network graphing feature of GeneNetwork confirmed that there was little correlation 
between weight loss kinetics and either the survival or time-to-death phenotypes  
(Figure 6-1).  
 
The in silico tools in GeneNetwork allowed us to identify candidate genes within 
the six previously identified QTL intervals that may be casual for resistance or 
susceptibility to a Bp infection. In total, there are 335 positional candidate genes located 
within these intervals. We were able to narrow down the total number of genes using 
QTLminer to 46 high scoring (score of 3 or 4) candidates using additional information 
such as normal gene expression levels in target organs, cis-regulation of the gene in the 
lung and number of nonsynonymous SNPs or indels between the parental B6 and D2 
genotypes. High scoring candidate genes within these intervals are involved in a wide 
range of pathways that could be important for mounting an effective immune response 
including, calcium homeostasis, cell stress responses, protein degradation and recycling, 
extracellular matrix and actin reorganization, apoptosis, bacterial phagocytosis, immune 
cell recruitment, tissue repair, lung homeostasis, cell cycle regulation and nervous system 
development.  
 
It has been suggested that variation in gene expression is an important contributor 
to the genetic architecture of complex traits [148]. To get a glimpse into the infection-
state gene regulation that may contribute to increased or decreased survival during a Bp 
infection, we performed host transcriptomic profiling using RNA-seq on the lung tissue 
of a small cohort of resistant (BXD -50, -70) and susceptible (BXD -09, -63, -70) BXD 
strains infected with Bp 1026b for 24 hours. This analysis revealed a very large number 
of host genes that were upregulated in the resistant or susceptible strains during a Bp 
infection. A gene ontology analysis provided insight into the common themes and 
biological significance of this large pool of data. Analysis outputs consistently 
demonstrated that the early host response in resistant strains, enriched for genes involved 
in the immediate immune responses, which include response to IFN-gamma, leukocyte 
activation, response to cytokine, and induction of apoptosis. The molecular function of 
the majority of genes upregulated in the resistant strains were involved in binding, which 
included antigen binding, chemokine receptor binding, and MHC class 1 and 1b protein 
binding. This cluster of genes significantly upregulated in the resistant strains represent a 
group of genes designated as “common host immune response”, and might signify a 
general “alarm signal” for inflammatory infections [201]. Based on the function of genes 
upregulated in the resistant strains we can infer that these genes allow activation of 
defense programs and control of intracellular bacterial replication. Meanwhile, the early 
host response in the susceptible strains enriched for genes involved in a variety of 
processes including vesicle-mediated transport, membrane organization, defense response 
and phagocytosis. Interestingly, there were genes also upregulated in the susceptible 
strains 24 hours post-infection that function in a response to hypoxia, which could be 
associated with the stress of anesthesia prior to intranasal installation. In fact, the timing 
of this transcript increase also correlates to the appearance of the transient weight loss  
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Figure 6-1. Correlation network for the survival, time-to-death, and weight loss 
phenotypes following pneumonic B. pseudomallei infection.   
 
The color of the lines connecting the B. pseudomallei disease-state traits indicate the 
following correlation indices: red line / 0.7 to 1.0, orange line / 0.5 to 0.7, green line / -
0.5 to -0.7, and blue line / -0.7 to -1.0.  
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QTLs that we hypothesize may have been a result of the effects of anesthesia prior to the 
Bp infection, similar to observations seen in the previously mentioned H1N1 study by 
Nedelko et. al. [73]. There were also a large number of genes that function in vesicle- 
mediated transport, which could function in many pathways including pathways that 
modulate the host defense response. Moreover, seeing as though Bp enters the host cell in 
a vesicle (endosome), these genes can also be implicated in increasing the permissiveness 
of Bp replication in establishing an intracellular colonization niche since our previous 
studies have illustrated that overwhelming bacterial loads are typical in the susceptible 
parental strain (D2). 
 
We went a step further and integrated the results of our RNA-Seq data with 
results from our QTL mapping studies. We mined this data to only incorporate genes that 
fell within any of our significant/suggestive QTL intervals. Using this approach, we were 
able to reduce the number of candidates from 46 genes residing throughout six QTL 
regions, to 10 high priority candidate genes on two QTLs (Chrs. 5 and 7) that were 
differentially expressed between the susceptible and resistant strains. Most notably, this 
analysis revealed a cluster of closely related interferon-gamma inducible genes, Cxcl9, 
Cxcl10, and Cxcl11, that encode the chemokine (C-X-C motif) ligands 9, 10, and 11, 
respectively and Ndn, which encodes the protein necdin (cell growth suppressor), all 
which were significantly up regulated in the resistant strains. Other genes generated from 
this analysis include Fam47e (family with sequence similarity 47), Prdm8 (protein 
domain containing 8), Chrna7 (neuronal acetylcholine receptor subunit alpha-7), Snrpa1 
(small nuclear ribonuclearprotein polypeptide), Tm2d3 (TM2 domain containing 3), and 
Gm20457 (not yet characterized), which were all significantly upregulated in the 
susceptible strains. These genes were further narrowed down to 4 potential candidate 
genes based on the genomic location of the gene of origin (cis vs. trans eQTLs). Cxcl9, 
Cxcl11, Ndn, and Chrna7 are all cis eQTLs that map to the same location as the 
expressed gene and therefore exert a direct effect on its function. Functional studies 
should commence with these genes as cis eQTLs generally have strong effect sizes and it 
is easier to validate and interpret their affect on the trait [202] when compared to trans 
eQTLs. Collectively, these results provided additional leverage for prioritization of 
candidate genes for further interrogation.  
 
The CXCL cluster of genes within our significant QTL region on chromosome 5 
is of particular interest based on their known biological function and their obvious role in 
immunity. Cxcl9 [also known as MIG, (monokine-induced by IFN-gamma)] and Cxcl11 
[I-TAC, (T cell alpha chemoattractant)] are interferon-gamma inducible chemokines that 
play a role in orchestrating immune cell accumulation (T cells, natural killer cells, and 
monocytes/macrophages) and activation during an inflammatory response [203]. They 
function through receptor dependent interactions through their cognate G-protein coupled 
receptor CXCR3 [170, 203]. Previous studies have illustrated that neutralization of these 
chemokines increases host susceptibility, thus the results of our gene expression profiling 
suggest that high expression of Cxcl9 and -11 is associated with increased survival since 
both are highly expressed in the resistant strains with an infection-state increase of 10 and 
24, respectively. Future experiments would incorporate functional studies to validate 
these candidate genes and explore their specific role during a Bp infection. For instance, 
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we could use many traditional techniques such as Reverse-Transcriptase PCR (RT-PCR), 
Real-time PCR (qPCR), ELISA, and RNA silencing, as previously described [47].  
Specifically, infection-state expression levels of the candidate genes, can be measured via 
RT-PCR and qPCR and differential protein expression can be measured by ELISA (or 
western blotting). Another ideal approach would be to use knockout mice or dampen the 
expression of the candidate genes using techniques such as RNA silencing in cells or 
animals that express a functional form of the gene. In addition, the use of congenic strains 
would be a valuable resource in analyzing our complex traits [204]. Congenic mice are 
genetically engineered to carry a targeted mutation where a small portion of the donor 
(mouse) genome is placed on a recipient mouse strain, allowing a defined chromosomal 
region to be assayed. In using these molecular techniques and others, we can begin to 
identify the functional roles of candidate genes that are responsible for observed 
differential infection-state phenotypes in mice during a Bp infection.  
 
In conclusion, there have been a number of studies that have identified host loci 
that are covariant with susceptibility to viral, bacterial, and even parasitic infectious 
agents. No clear pattern has emerged from these studies, and in fact, collectively their 
findings indicate that host-pathogen interactions are extremely complex. Some of these 
studies have identified single host loci that are responsible for disease susceptibility, 
while others have determined that susceptibility to disease involves multiple host loci. 
For instance, it has been documented that a single gene (Scl2) controls the predisposition 
for development of cutaneous lesions following infection with Leishmania mexicana 
[115]. It has also been shown that susceptibility to murine cytomegalovirus is controlled 
by a single host loci that encodes an NK cell activating receptor [118, 119] and that a 
single gene (Car2) serves as the susceptibility locus for Theiler's virus-induced 
demyelinating disease [120]. In contrast, similar studies have revealed that susceptibility 
to influenza virus infection is a multigenic trait, and that different arrays of host loci 
control susceptibility to distinct strains of influenza [73, 123]. Studies of susceptibility to 
bacterial pathogens have also yielded divergent results. A set of studies by Miyairi and 
associates revealed that susceptibility to Chlamydia psittaci is a simple trait that is 
controlled by a single host locus that encodes p47 GTPases [74, 100]. Another study 
revealed that differential susceptibility to group A Steptococci is also controlled by a 
single host genetic locus [122]. In contrast, a study by Yadav and colleagues [121] and 
the present study revealed that susceptibility to the bacterial pathogens Yersina pestis and 
Bp, respectively, involve multiple host loci. In fact, the only clear similarity between 
these two studies was that two of the weaker QTLs involved in susceptibility to Yersinia 
overlap with the QTL on chromosome 5 that was identified in the current studies on Bp. 
These similarities could be coincidental, but they could also indicate some strong 
similarities in the interactions of hosts with these two highly virulent intracellular 
bacterial pathogens.  
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FUTURE STUDIES 
 
 
Chromosomes 5 and 7 Are Co-Dependent 
 
Whole genome linkage analysis of our survival phenotype revealed two 
significant QTLs on chromosomes 5 and 7. The significant/suggestive regions of these 
two chromosomes have roughly the same pattern of inheritance of B6 and D2 haplotypes 
from the 32-BXD strain cohort used in the initial analysis. In other words, our significant 
and suggestive intervals on chromosomes 5 and 7 are effectively one region of the 
genome from a statistical point of view. GN incorporates a feature called composite 
interval mapping, which can detect secondary QTLs and decipher if two loci are co-
dependent or independent. Composite interval mapping revealed that these two loci are 
co-dependent based on the loss of both QTLs when we controlled for loci within or near 
the significant/suggestive QTL intervals for chromosomes 5 and 7.  
 
While previous studies were completed using randomly selected BXD strains, to 
resolve the co-dependency between chromosomes 5 and 7, we have begun adding 
specifically selected strains to the previous analysis. These specifically selected strains 
were chosen based on the results of a haplotype analysis that was completed using GN. 
The haplotype analysis identified BXD genotypes (that were not used in the preliminary 
studies) that have differing haplotypes (either B6 or D2) on chromosomes 5 and 7 in our 
regions of interest. Same as previous studies, disease-state phenotypes (survival, time-to-
death and weight loss) were measured using the selected BXD strains. Recently, we have 
added three new BXD strains (BXD -44, -79, -100) to this analysis and interval mapping 
revealed a highly significant QTL on chromosome 5 (Figure 6-2). The QTL peak on 
chromosome 7 from our initial analysis was a presumed artifact attributable to the similar 
pattern of inheritance in the initial BXD cohort and addition of these strains with 
differing haplotypes, significantly decreased the QTL on chromosome 7. We will 
continue to add specifically selected BXD strains to this study to increase the precision of 
QTL analysis and significantly reduce the number of candidate genes.  
 
 
The Additive Allele Effect for Survival QTL Analysis 
 
Future studies will focus on an interesting phenomenon observed during our 
survival QTL analysis involving the additive allele effect. The additive allele effect is an 
estimate of the change in the average phenotype that would be produced by substituting a 
D2 or B6 single allele, thereby increasing trait values [205, 206]. When observing a QTL 
map generated by GN, the thin red and green lines indicate that B6 or D2 alleles increase 
trait values, respectively, and the additive values are located on the far right of the QTL 
map [205]. QTL maps of our survival phenotype display a thin green line, which is 
indicative of a D2 allele increasing the survival trait in the suggestive/significant QTL 
interval on chromosomes 5; but this observation does not conform to what we observe for 
survival at the parental level. Based on our QTL maps, B6 should be a highly sensitive 
strain and D2 should be a highly resistant strain. We postulate that something dramatic  
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Figure 6-2. Refined QTL analysis with addition of three new BXD genotypes: 
Genome-wide linkage analysis of survival following pneumonic challenge with 
Burkholderia pseudomallei. 
 
A cohort of male mice, which included 35 BXD strains, was infected intranasally with 
50-100 CFU of Burkholderia pseudomallei.  Infected mice were monitored for survival 
for up to 11 days post-infection and those that survived infection were given a value of 
“1” while those that succumbed to infection received a value of “0”. Panel A: Log-Rank 
plot showing the mean± SEM of the survival value for each strain. Panels B and C: 
Standard and weighted interval mapping, respectively, was performed using the in silico 
resources within GeneNetwork.org to identify genetic loci that correlated with survival. 
The blue line indicates LRS scores across the entire genome. Thin red and green lines 
indicate that B6 or D2 alleles increase trait values, respectively. The mouse chromosomes 
are identified in the upper x-axis, the lower x-axis shows the physical map in mega bases 
for each chromosome, and the y-axis represents the LRS score. Thick red and grey 
horizontal lines indicate the genome-wide significance threshold (p<0.05) or suggestive 
threshold (p<0.63), respectively.
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has happened in this region of the genome in one of the parent strains that has caused a 
reverse in the polarity. However, it is unlikely that both strains were subject to a serious 
mutation that would cause this type of reverse in polarity. Undeniably, this phenomenon 
raises the following question: In the last 20 years, has there been a serious mutation in D2 
that has made it more sensitive to Bp or has there been a mutation in B6 that has made it 
highly resistant to Bp? A haplotype analysis revealed that mice with a B allele within our 
QTL intervals on chromosome 5 succumb to Bp infection, while mice with a D allele 
display an increased survival phenotype to the infection. 
 
One way to begin dissecting this interesting observation is to perform Bp survival 
studies with C57BL/6NJ (B6NJ) mice. Using B6NJ mice will allow us to test the idea 
that there has been a novel or spontaneous mutation in the B6 strain that has permitted 
them to survive Bp infections. In 1951, The Jackson Laboratory sent B6 mice (at F32 
generation) to the National Institutes of Health, where they were maintained and bred 
independently for decades [207]. B6NJ is now considered a subline of C57BL/6. As such, 
if a recent mutation is the cause of the increased survivability in the B6 mice, then the 
B6NJ strains would be devoid of this mutation and exhibit a decreased survival 
phenotype. Conversely, this same study could be carried out with D2 mice using DBA/1J 
(D1).  D2 and D1 differ at a large number of loci (including the MHC H2 haplotype).  
 
 
CONCLUSIONS 
The mapping of host resistance and susceptibility loci in the BXD RI population 
uncovered several QTLs and potential candidate genes that may be critical for host 
defense during melioidosis. The data presented in this dissertation provides an intriguing 
glimpse into the genetic basis of the differential susceptibility to a Bp infection. Our data 
indicate that genetic regulation of survival, time-to-death and weight loss during a Bp 
infection is a complex phenomenon, whereby many genes exert their effects on these 
traits. Weight loss QTLs displayed a time-dependent profile indicating host loci within 
these QTLs may be important for the host response in a transient and dynamic fashion. 
Furthermore, linkage analysis of survival (and time-to-death) generated two significant 
QTLs, but we were able to narrow down these QTL regions to chromosome 5 only using 
specifically selected BXD strains. We examined these QTL regions and identified several 
possible candidate genes that may be important for host response to Bp infections. These 
studies will lay the groundwork in increasing our understanding of the interactions 
between Bp and its genetically diverse hosts.  
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APPENDIX.    SUPPLEMENTARY FIGURES AND TABLES 
 
 
Table A-1.    BXD strain group sizes from day 1 through day 4. 
 
Day #1   Day #2   Day #3   Day #4 
Mouse 
Strain 
n=# of 
mice 
 Mouse 
Strain 
n=# of 
mice 
 Mouse 
Strain 
n=# of 
mice 
 Mouse 
Strain 
n=# of 
mice 
C57BL/6J n=23   C57BL/6J n=23   C57BL/6J n=23   C57BL/6J n=23 
DBA n=23   DBA n=23   *DBA n=22   *DBA n=3 
BXD 27 n=1   BXD 27 n=1   BXD 27 n=1   BXD 27 n=1 
BXD 22 n=3   BXD 22 n=3   BXD 22 n=3   BXD 22 n=3 
BXD 90 n=6   BXD 90 n=6   BXD 90 n=6   BXD 90 n=6 
BXD 55 n=11   BXD 55 n=11   BXD 55 n=11   BXD 55 n=11 
BXD 49 n=8   BXD 49 n=8   BXD 49 n=8   BXD 49 n=8 
BXD 81 n=8   BXD 81 n=8   BXD 81 n=8   *BXD 81 n=4 
BXD 73 n=10   BXD 73 n=10   BXD 73 n=10   *BXD 73 n=6 
BXD 87 n=8   BXD 87 n=8   BXD 87 n=8   BXD 87 n=8 
BXD 95 n=2   BXD 95 n=2   BXD 95 n=2   BXD 95 n=2 
BXD 103 n=12   BXD 103 n=12   *BXD 103 n=11   *BXD 103 n=10 
BXD 9 n=6   BXD 9 n=6   *BXD 9 n=5   *BXD 9 n=3 
BXD 45 n=3   BXD 45 n=3   BXD 45 n=3   BXD 45 n=3 
BXD 75 n=6   BXD 75 n=6   BXD 75 n=6   BXD 75 n=6 
BXD 50 n=5   BXD 50 n=5   BXD 50 n=5   BXD 50 n=5 
BXD 63 n=4   BXD 63 n=4   BXD 63 n=4   *BXD 63 n=1 
BXD 101 n=1   BXD 101 n=1   BXD 101 n=1   BXD 101 n=1 
BXD 65 n=1   BXD 65 n=1   BXD 65 n=1   BXD 65 n=1 
BXD 96 n=12   BXD 96 n=12   BXD 96 n=12   *BXD 96 n=9 
BXD 74 n=8   BXD 74 n=8   BXD 74 n=8   BXD 74 n=8 
BXD 80 n=4   BXD 80 n=4   BXD 80 n=4   BXD 80 n=4 
BXD 67 n=8   BXD 67 n=8   BXD 67 n=8   *BXD 67 n=5 
BXD 64 n=19   BXD 64 n=19   BXD 64 n=19   *BXD 64 n=14 
BXD 86 n=10   BXD 86 n=10   BXD 86 n=10   *BXD 86 n=2 
BXD 13 n=4   BXD 13 n=4   BXD 13 n=4   *BXD 13 n=1 
BXD 12 n=4   BXD 12 n=4   BXD 12 n=4   BXD 12 n=4 
BXD 43 n=11   BXD 43 n=11   BXD 43 n=11   *BXD 43 n=8 
BXD 1 n=2   BXD 1 n=2   BXD 1 n=2   *BXD 1 n=1 
BXD 62 n=16   BXD 62 n=16   BXD 62 n=16   *BXD 62 n=12 
BXD 69 n=5   BXD 69 n=5   BXD 69 n=5   *BXD 69 n=4 
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Table A-1.    (Continued). 
 
Day #1   Day #2   Day #3   Day #4 
Mouse 
Strain 
n=# of 
mice 
Mouse 
Strain 
n=# of 
mice 
 Mouse 
Strain 
n=# of 
mice 
 Mouse 
Strain 
n=# of 
mice 
BXD 66 n=4   BXD 66 n=4   BXD 66 n=4   BXD 66 n=4 
BXD 68 n=4   BXD 68 n=4   BXD 68 n=4   *BXD 68 n=1 
BXD 38 n=1   BXD 38 n=1   BXD 38 n=1   BXD 38 n=1 
 
Red asterisk (*) indicates that at least one mouse from that genotype succumbed to 
infection.  
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Figure A-1.    Genome-wide linkage analysis for percentage weight loss on days 5-11 
post-Bp infection. 
 
Genome-wide interval maps of percentage weight loss of all BXD genotypes and parental 
strains at each time point are shown as indicated. Days 5, 8 and 9 show a significant QTL 
on chromosome 12 while days 6, 7, 10, 11 show a suggestive QTL on chromosome 12. 
The blue line indicates LRS scores across the entire genome. Thin red and green lines 
indicate that B6 or D2 alleles increase trait values, respectively. The mouse chromosomes 
are identified in the upper x-axis, the lower x-axis shows the physical map in mega bases 
for each chromosome, and the y-axis represents the LRS score. Thick red and grey 
horizontal lines indicate the genome-wide significance threshold (p<0.05) or suggestive 
threshold (p<0.63), respectively.  
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Table A-2.    Pathway analysis (Gene Ontology (GO) Description) using genes whose 
expression is significantly upregulated in resistant BXD mice (BXD50 and BXD70).  
 
GO-Description Count % P-Value Benjamini 
immune response 56 14.1 3.60E-28 5.80E-25 
defense response 32 8.1 5.50E-10 2.90E-07 
response to wounding 21 5.3 1.20E-05 2.10E-03 
response to organic substance 19 4.8 8.50E-03 3.10E-01 
regulation of cell proliferation 19 4.8 1.50E-02 4.30E-01 
regulation of apoptosis 18 4.5 3.70E-02 6.00E-01 
regulation of programmed cell death 18 4.5 4.10E-02 6.20E-01 
regulation of cell death 18 4.5 4.30E-02 6.20E-01 
inflammatory response 16 4 2.90E-05 4.60E-03 
response to virus 15 3.8 1.50E-10 1.20E-07 
antigen processing and presentation 14 3.5 9.90E-09 4.00E-06 
positive regulation of immune 
system process 
14 3.5 1.70E-04 1.60E-02 
behavior 14 3.5 4.80E-02 6.40E-01 
innate immune response 12 3 6.20E-06 1.40E-03 
positive regulation of immune 
response 
11 2.8 2.80E-04 2.30E-02 
positive regulation of response to 
stimulus 
11 2.8 3.10E-03 1.60E-01 
positive regulation of apoptosis 11 2.8 2.10E-02 5.00E-01 
positive regulation of programmed 
cell death 
11 2.8 2.20E-02 5.10E-01 
positive regulation of cell death 11 2.8 2.30E-02 5.10E-01 
regulation of lymphocyte mediated 
immunity 
10 2.5 3.80E-06 1.00E-03 
regulation of leukocyte mediated 
immunity 
10 2.5 7.00E-06 1.40E-03 
regulation of immune effector 
process 
10 2.5 4.60E-05 6.10E-03 
positive regulation of multicellular 
organismal process 
10 2.5 4.20E-03 1.90E-01 
lymphocyte activation 10 2.5 1.10E-02 3.70E-01 
leukocyte activation 10 2.5 2.50E-02 5.20E-01 
locomotory behavior 10 2.5 4.10E-02 6.20E-01 
cell activation 10 2.5 4.70E-02 6.40E-01 
regulation of cytokine production 9 2.3 5.30E-03 2.30E-01 
  88 
Table A-2.    (Continued). 
 
GO-Description Count % P-Value Benjamini 
 
induction of programmed cell death 9 2.3 1.50E-02 4.30E-01 
induction of apoptosis 9 2.3 1.50E-02 4.30E-01 
positive regulation of signal 
transduction 
9 2.3 1.80E-02 4.60E-01 
response to endogenous stimulus 9 2.3 2.50E-02 5.20E-01 
positive regulation of cell 
communication 
9 2.3 2.90E-02 5.40E-01 
regulation of cell killing 8 2 1.20E-06 3.90E-04 
regulation of leukocyte mediated 
cytotoxicity 
8 2 1.20E-06 3.90E-04 
regulation of adaptive immune 
response based on somatic 
recombination of immune receptors 
built from immunoglobulin 
superfamily domains 
8 2 9.00E-05 9.70E-03 
regulation of adaptive immune 
response 
8 2 9.00E-05 9.70E-03 
T cell activation 8 2 6.90E-03 2.70E-01 
immune effector process 8 2 1.10E-02 3.60E-01 
positive regulation of transport 8 2 1.30E-02 4.10E-01 
regulation of lymphocyte activation 8 2 2.10E-02 5.00E-01 
regulation of leukocyte activation 8 2 2.90E-02 5.50E-01 
regulation of cell activation 8 2 3.00E-02 5.50E-01 
regulation of protein modification 
process 
8 2 3.90E-02 6.20E-01 
response to hormone stimulus 8 2 3.90E-02 6.20E-01 
antigen processing and presentation 
of peptide antigen 
7 1.8 4.70E-05 5.80E-03 
positive regulation of leukocyte 
mediated immunity 
7 1.8 1.00E-04 1.00E-02 
positive regulation of lymphocyte 
mediated immunity 
7 1.8 1.00E-04 1.00E-02 
positive regulation of immune 
effector process 
7 1.8 2.30E-04 2.00E-02 
lipoprotein metabolic process 7 1.8 3.30E-03 1.70E-01 
regulation of T cell activation 7 1.8 1.80E-02 4.60E-01 
regulation of protein amino acid 
phosphorylation 
7 1.8 2.90E-02 5.40E-01 
positive regulation of cell killing 6 1.5 6.30E-05 7.20E-03 
positive regulation of adaptive immune 
response based on somatic recombination 
of immune receptors built from 
immunoglobulin superfamily domains 
6 1.5 4.40E-04 3.20E-02 
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positive regulation of adaptive 
immune response 
6 1.5 4.40E-04 3.20E-02 
positive regulation of cytokine 
production 
6 1.5 6.60E-03 2.70E-01 
negative regulation of immune 
system process 
6 1.5 1.50E-02 4.30E-01 
adaptive immune response 6 1.5 2.20E-02 5.10E-01 
adaptive immune response based on 
somatic recombination of immune 
receptors built from 
immunoglobulin superfamily 
domains 
6 1.5 2.20E-02 5.10E-01 
negative regulation of multicellular 
organismal process 
6 1.5 4.30E-02 6.30E-01 
regulation of T cell mediated 
cytotoxicity 
5 1.3 3.90E-05 5.70E-03 
regulation of T cell mediated 
immunity 
5 1.3 3.20E-04 2.50E-02 
antigen processing and presentation 
of exogenous antigen 
5 1.3 1.90E-03 1.10E-01 
positive regulation of defense 
response 
5 1.3 2.30E-02 5.00E-01 
antigen processing and presentation 
via MHC class Ib 
4 1 2.30E-04 1.90E-02 
positive regulation of T cell 
mediated cytotoxicity 
4 1 5.30E-04 3.70E-02 
positive regulation of T cell 
mediated immunity 
4 1 1.70E-03 1.10E-01 
regulation of interleukin-12 
production 
4 1 2.70E-03 1.50E-01 
antigen processing and presentation 
of peptide antigen via MHC class I 
4 1 3.90E-03 1.90E-01 
regulation of natural killer cell 
mediated cytotoxicity 
4 1 6.20E-03 2.60E-01 
regulation of natural killer cell 
mediated immunity 
4 1 6.20E-03 2.60E-01 
antigen processing and presentation 
of exogenous peptide antigen 
4 1 9.20E-03 3.30E-01 
regulation of interferon-gamma 
production 
4 1 2.30E-02 5.10E-01 
response to cytokine stimulus 4 1 2.30E-02 5.10E-01 
negative regulation of mononuclear 
cell proliferation 
4 1 2.90E-02 5.40E-01 
negative regulation of leukocyte 
proliferation 
4 1 2.90E-02 5.40E-01 
negative regulation of lymphocyte 
proliferation 
4 1 2.90E-02 5.40E-01 
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cell growth 4 1 3.30E-02 5.70E-01 
positive regulation of cytokine 
biosynthetic process 
4 1 4.60E-02 6.40E-01 
antigen processing and presentation 
of endogenous peptide antigen 
3 0.8 2.10E-03 1.20E-01 
positive regulation of glucose 
transport 
3 0.8 7.20E-03 2.80E-01 
positive regulation of glucose 
import 
3 0.8 7.20E-03 2.80E-01 
positive regulation of interleukin-12 
biosynthetic process 
3 0.8 7.20E-03 2.80E-01 
regulation of interleukin-12 
biosynthetic process 
3 0.8 1.20E-02 3.80E-01 
regulation of fibroblast growth 
factor receptor signaling pathway 
3 0.8 1.80E-02 4.60E-01 
regulation of peptidyl-serine 
phosphorylation 
3 0.8 1.80E-02 4.60E-01 
cytokine metabolic process 3 0.8 2.90E-02 5.50E-01 
defense response to virus 3 0.8 3.30E-02 5.70E-01 
cell structure disassembly during 
apoptosis 
3 0.8 3.30E-02 5.70E-01 
positive regulation of natural killer 
cell mediated immunity 
3 0.8 3.30E-02 5.70E-01 
positive regulation of natural killer 
cell mediated cytotoxicity 
3 0.8 3.30E-02 5.70E-01 
positive regulation of interferon-
gamma production 
3 0.8 4.10E-02 6.10E-01 
negative regulation of neurological 
system process 
3 0.8 4.60E-02 6.40E-01 
antigen processing and presentation 
of endogenous peptide antigen via 
MHC class Ib 
2 0.5 3.80E-02 6.10E-01 
 
Count - number of genes from list involved in GO Description; % - percentage of all 
genes in list; P-value - modified Fisher Exact p-value for enrichment; Benjamini - false 
discovery rate corrected P-values. 
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Table A-3.    Pathway analysis (Gene Ontology (GO) Description) using genes whose 
expression is significantly upregulated in susceptible BXD mice (BXD9, BXD63 and 
BXD27). 
 
GO-Description Count % P-Value Benjamini 
 
vesicle-mediated transport 16 6.2 1.80E-04 6.80E-02 
membrane organization 14 5.4 9.20E-06 5.20E-03 
defense response 13 5 3.80E-03 5.80E-01 
endocytosis 12 4.7 7.00E-06 7.90E-03 
membrane invagination 12 4.7 7.00E-06 7.90E-03 
response to wounding 10 3.9 1.40E-02 8.40E-01 
intracellular transport 10 3.9 4.80E-02 9.00E-01 
ion homeostasis 9 3.5 1.50E-02 8.30E-01 
translation 9 3.5 2.40E-02 9.00E-01 
chemical homeostasis 9 3.5 4.80E-02 8.90E-01 
cellular ion homeostasis 8 3.1 2.50E-02 8.90E-01 
cellular chemical 
homeostasis 
8 3.1 2.80E-02 8.90E-01 
positive regulation of 
multicellular organismal 
process 
7 2.7 9.10E-03 7.80E-01 
inflammatory response 7 2.7 3.80E-02 8.80E-01 
defense response to 
bacterium 
6 2.3 6.70E-03 7.20E-01 
response to bacterium 6 2.3 2.90E-02 8.80E-01 
phagocytosis 4 1.6 1.60E-02 8.20E-01 
response to hypoxia 4 1.6 3.30E-02 8.80E-01 
response to oxygen levels 4 1.6 3.40E-02 8.80E-01 
regulation of cAMP 
metabolic process 
4 1.6 3.70E-02 8.80E-01 
regulation of cyclic 
nucleotide metabolic 
process 
4 1.6 4.60E-02 9.00E-01 
regulation of nucleotide 
metabolic process 
4 1.6 4.90E-02 8.90E-01 
inflammatory response to 
antigenic stimulus 
3 1.2 2.40E-03 5.00E-01 
cell killing 3 1.2 1.30E-02 8.40E-01 
positive regulation of 
phagocytosis 
3 1.2 2.60E-02 8.80E-01 
regulation of phagocytosis 3 1.2 3.00E-02 8.70E-01 
antibody-dependent cellular 
cytotoxicity 
2 0.8 4.30E-02 9.00E-01 
type IIa hypersensitivity 2 0.8 4.30E-02 9.00E-01 
type II hypersensitivity 2 0.8 4.30E-02 9.00E-01 
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Count - number of genes from list involved in GO Description; % - percentage of all 
genes in list; P-value - modified Fisher Exact p-value for enrichment; Benjamini - false 
discovery rate corrected P-values. 
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